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ABSTRACT 
 
The receptor tyrosine kinase, RON, is expressed on tissue-resident 
macrophages.  RON functions by activating genes that promote wound repair 
and resolve inflammation, while repressing genes that perpetuate tissue damage 
and cell death. Chronic HIV infection is associated with dysregulated 
inflammation, and we hypothesize that diminished macrophage RON expression 
contributes to the development of end organ diseases including HIV-associated 
central nervous system (CNS) inflammation. We utilized CNS tissue from a SIV 
macaque model to examine the temporal regulation of RON in the brain during 
infection. Following prolonged SIV infection, RON expression was inversely 
correlated with the development of CNS disease: RON was highly expressed in 
animals that did not develop CNS lesions and lower in SIV infected macaques 
that demonstrated moderate to severe inflammatory lesions.   Arginase-1  
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expression was low during late infection whereas expression of the inflammatory 
genes, IL-12 p40 and TNFα, was elevated compared to uninfected animals.  To 
validate a role for RON in regulating HIV, we infected human tonsillar tissue-
resident macrophages.  RON inhibited HIV replication in tissue-resident 
macrophages. Furthermore, HIV infection diminished RON in tonsil 
macrophages. We propose a model in which RON expression is decreased, 
genes that quell inflammation are repressed, and inflammatory mediators are 
induced to promote tissue inflammation following chronic HIV infection in the 
brain.  
 The cyclin dependent kinase inhibitor p21 is a factor that, like RON, 
negatively regulates HIV transcription.  Elevated expression of p21 in HIV+ elite 
controllers, or by ectopic expression in primary CD4+ T cells, resulted in reduced 
HIV expression.  Furthermore, these elite controllers had increased binding of 
factors that negatively regulate transcription elongation at the HIV long terminal 
repeat. 
RON and p21 are examples of cellular factors that limit HIV transcription 
and contribute to HIV latency.  Latently infected cells are not targeted by anti-
retroviral therapy and permit rapid rebound of viremia following treatment 
interruption.  Understanding intrinsic mechanisms that establish latency may 
provide targets for purging these HIV reservoirs or maintaining their 
transcriptionally silent state. 
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INTRODUCTION 
 
Significance 
An estimated 34 million people world-wide are human immunodeficiency 
virus (HIV) positive, including approximately 2.5 million new cases annually 
(UNAIDS, 2012).  In spite of the relative success of combined anti-retroviral 
therapy (ART), that targets multiple steps of the HIV-1 replication cycle, 1.7 
million acquired immune deficiency syndrome (AIDS)-related deaths occur yearly 
(UNAIDS, 2012).   The greatest impact of HIV/AIDS remains in areas of Sub-
Saharan Africa where socio-economic limitations have prevented universal 
access to anti-retroviral therapy (Vella et al., 2012).  Current anti-retroviral 
regimens have commuted an HIV diagnosis from an immediate death sentence 
to life coping with the virus, while the patient remains continuously dependent on 
ART.  Furthermore, interruption of ART results in rapid rebound in viremia (Finzi 
et al., 1997; Wong et al., 1997) and generation of HIV mutants that may require a 
new combination of drugs to regain viral suppression.  While current treatments 
effectively repress HIV replication in infected individuals, a cure remains elusive.   
In addition to infection and depletion of CD4+ cells, HIV-1 infection is 
characterized by a general immune dysfunction which results in a number of 
secondary infections and comorbidities which together contribute to the 
multifactorial disease known as AIDS (Chang et al., 2013; Marin et al., 2009).   
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Although ART has been successful at suppressing viral replication, it does not 
target these secondary immune-driven disorders.    
 
HIV and AIDS disease pathogenesis 
Defining characteristics of HIV-1 infection 
Infection of CD4+ T cells is the hallmark of HIV infection, and depletion of 
these cells is a defining characteristic of disease progression.  CD4+ T cell counts 
are used as a measure of health in HIV-infected individuals, as well as a 
common diagnostic indicator for when to initiate ART.  While CD4 T cell counts 
under 500 cells/ μl were once considered the standard for initiation of ART, more 
recent recommendations have suggested initiating treatment upon HIV 
diagnosis, as this has been reported to lead to more favorable outcome 
(UNAIDS, 2012).   
Immature monocytes, the precursors to macrophages, are not efficiently 
infected by HIV (Bergamaschi and Pancino, 2010).  However, upon maturation 
into macrophages, the cells become permissive to HIV infection, but are resistant 
to the cytopathic effects of the virus (Cassol et al., 2006; Cobos-Jimenez et al., 
2011; Koppensteiner et al., 2012; Verani et al., 2005).  Macrophages are 
relatively quiescent, terminally differentiated, long lived cells; and are potentially 
a long term reservoir for HIV (Crowe et al., 2003).   HIV infection of macrophages 
results in dysfunction in their ability to respond appropriately to immune stimuli, 
and results in elevated inflammatory cytokines (Kedzierska et al., 2002; Renga et 
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al., 2012; Yadav and Collman, 2009).  Infected macrophages are unable to 
suitably respond to inflammatory stimuli and therefore play an important role in 
the inflammatory disorders, metabolic diseases, and susceptibility to other 
infectious pathogens observed in HIV+ individuals (Kedzierska et al., 2002; Marin 
et al., 2009; Verani et al., 2005).  Both the direct effects of the virus on the host 
immune cells and bystander effects of the dysregulated cytokine milieu result in 
the immune dysfunction associated with AIDS. 
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Figure 1.  Structure of HIV-1 particles and HIV-1 genome organization.   
(A)  Structural proteins of the HIV particle include the envelope (gp 41 and 
gp120), matrix, capsid, and nucleocapsid.  Within the capsid are the accessory 
 
5 
 
proteins (vif, vpr, and nef), the RNA genome, and viral enzymes: protease, 
integrase, and reverse transcriptase.  (B)  The HIV-1 genome encodes for three 
structural genes (gag, env, and pol) and six accessory genes (vif, vpr, vpu, tat, 
rev, and nef).  The HIV genome is transcribed, and gag, pol and env are 
translated as polyprotein pre-cursors, which are cleaved by protease into the 
functional proteins.  Gag is cleaved into matrix, capsid, and nucleocapsid.   Env 
is cleaved into gp 120 and gp41.  Pol is cleaved into protease, integrase and 
reverse transcriptase. 
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 HIV classification 
HIV was first discovered in the early 1980’s as the causative pathogen 
responsible for AIDS (Sharp and Hahn, 2011).  HIV-1 is a member of the 
Retroviridae family, which are classified by their ability to convert their RNA 
genome into proviral DNA using reverse transcription. HIV-1 belongs to the 
Lentivirus subfamily, which also includes HIV-2 and simian immunodeficiency 
virus (SIV); infection with these retroviruses is characterized by a long 
asymptomatic period before clinical symptoms manifest.  The disease outcome 
of infection with HIV and SIV differ in their natural host (Apetrei et al., 2004; 
Sharp and Hahn, 2011).  Whereas HIV-1 infection results in a severe immune 
dysfunction, SIV infection does not cause pathogenesis in its natural simian 
hosts, the exception being SIVcpz which causes AIDS-like disease in 
chimpanzees.   
 
HIV replication cycle 
HIV-1 enters the host cell via receptor-mediated fusion, relying on 
recognition of the viral envelope protein gp120 by the CD4 receptor and a 
chemokine co-receptor, either CCR5 or CXCR4 (Fig. 1-2).  While CD4+ T cells 
are the primary target of HIV-1, macrophages also express CD4 and the 
appropriate chemokine receptors, and consequently are targeted for infection 
(Henrich and Kuritzkes, 2013).  Upon binding of CD4 and the chemokine co-
receptors, the envelope undergoes conformational changes, exposing the gp41 
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fusion peptide and facilitating insertion into the host cell membrane, resulting in 
membrane fusion and entry of the viral genome into the host cytoplasm.  Within 
the cell, the viral reverse transcriptase creates a double stranded DNA provirus 
which is translocated to the nucleus where viral integrase inserts the provirus into 
the host genome.  The provirus integrates with a bias towards transcriptionally 
active genes which have an open chromatin structure and provide a more 
accessible target for integration (Schroder et al., 2002; Wang et al., 2007).  Once 
integrated into the host genome, HIV-1 usurps the host transcription machinery 
to generate viral RNA.  The HIV RNA transcript is differentially processed by host 
splicing machinery and the viral factor Rev, resulting in mRNA for HIV structural 
and accessory proteins as well as the HIV genomic RNA (Tazi et al., 2010).  Viral 
proteins are translated and targeted to assemble at the plasma membrane.  
Virions bud from the plasma membrane, thereby incorporating components 
associated the cellular plasma membrane, such as specialized glycolipids, 
proteins, and intracellular signaling molecules into the newly formed virion (Meng 
and Lever, 2013; Schiralli Lester et al., 2013).  Within the released virion, HIV 
protease further cleaves Gag, resulting in a mature virion, capable of infecting 
other cells.   
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Figure 2.  HIV replication cycle.   HIV-1 envelope proteins bind CD4 and a 
chemokine co-receptor (CCR5 of CXCR4) on the surface of human CD4+ T cells 
and macrophages.  Following membrane fusion and entry, the HIV-1 capsid 
uncoats and releases its contents into the host cytoplasm.  The HIV-1 single 
stranded RNA genome is converted into a double stranded DNA provirus by 
reverse transcriptase.  The provirus enters the nucleus and is inserted randomly 
into the host genome via the action of integrase.  Following transcription (see Fig. 
3), viral mRNA is shuttled out of the nucleus and either translated into viral 
proteins, or assembled into newly formed virions at the host cell plasma 
membrane. The virus buds and releases, incorporating cell membrane proteins 
into the newly formed virion membrane. 
 
9 
 
HIV Transcription   
HIV transcription is regulated by the HIV 5’ long terminal repeat (LTR) 
which acts as a promoter and enhancer (Fig. 3).  The LTR has binding sites for a 
number of host transcription factors, including NF-κB, AP-1, and CEBP/β 
(Berkhout and Jeang, 1992; Henderson et al., 1995; Kawakami et al., 1988; 
Schiralli Lester and Henderson, 2012).   HIV-1 does not produce its own RNA 
polymerase, and instead relies on the host RNA polymerase II (Pol II) to 
transcribe the integrated HIV provirus into an RNA transcript.  In the same 
manner as host transcription, Pol II is recruited by general transcription factors to 
the HIV LTR where the Pol II carboxyl terminal domain (CTD) is phosphorylated 
at the Serine 5 position (Fig. 3a) (Trigon et al., 1998).  This allows Pol II to 
process a short distance past the transcription start site, where it then pauses.  
Pol II pausing is a normal check point in transcriptional elongation (Hargreaves et 
al., 2009; Liang et al., 2006).   
HIV Pol II pausing is maintained, in part, by nucleosome structure.  Post-
translational modifications to histones, including acetylation and methylation, 
alter the association of a nucleosome with DNA and the accessibility of that DNA 
to transcription complexes including Pol II (Fig. 3b).   For example, acetylated 
histone 3 (H3) and H4 are associated with open chromatin structure (Pumfery et 
al., 2003; Van Lint et al., 1996).  Acetylated lysine residues decrease the 
negative charge of histones, which reduces their interaction with negatively 
charged phosphate groups on DNA.  Histone acetylation is regulated by two sets 
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of enzymes: histone acetyl transferases (HAT) enzymes such as p300/CBP, 
GCN5 and PCAF, and histone deacetylase complexes (HDACs) (Williams et al., 
2006).  In addition to acetylation, methylation of lysine residues on histones also 
regulates chromatin structure (Sakane et al., 2011; Williams et al., 2006).  
Methylation is a mark for both active and repressive chromatin structure 
dependent on the position of the targeted lysine residue as well as the number of 
methyl groups added to a specific residue.  In addition to post-translational 
modifications to histones, ATP-dependent chromatin remodeling complexes, 
such as SWItch/Sucrose NonFermentable (SWI/SNF), are recruited to further 
destabilize the interaction between DNA and histones (Mahmoudi et al., 2006; 
Treand et al., 2006).   
HIV encodes for a trans-activator of transcription (Tat), which enhances 
the processivity of HIV transcription (Fig. 3c) (Benkirane et al., 1998; Berkhout 
and Jeang, 1992).  An RNA stem loop is formed on the nascent RNA at the 5’ 
end of the HIV transcript, the Tat activating region (TAR).   Tat binds TAR, and 
recruits the positive transcription elongation factor b (P-TEFb) to the HIV-1 LTR 
facilitating transcription elongation and relief of the paused Pol II (Fig. 3c).  P-
TEFb is a complex of proteins, including cyclin T1 and cyclin dependent kinase 9 
(CDK9) (Bres et al., 2008).  The kinase activity of CDK9 phosphorylates the 
Serine 2 residue on the Pol II CTD as well as DRB-sensitive inhibitory factor 
(DSIF) and negative elongation factor (NELF), causing the dissociation of NELF 
from the Pol II complex (Fujinaga et al., 2004; Natarajan et al., 2013; Wu et al., 
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2003; Zhang et al., 2007b).  Phosphorylated DSIF remains associated with 
processive Pol II and facilitates HIV transcription elongation (Yamada et al., 
2006). Release of NELF, and associated inhibitory molecules, concurrent with 
the recruitment of nucleosome remodeling enzymes such as HATs (Benkirane et 
al., 1998; Steger et al., 1998) and SWI/SNF (Mahmoudi et al., 2006; Treand et 
al., 2006), facilitates a less restrictive chromatin structure, thereby permitting 
productive elongation.   
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Figure 3.  Regulation of HIV transcription.  (A)  HIV-1 transcription initiation is 
mediated by recruitment of host cellular transcription factors, including C/EBPβ, 
NFκB (p65 and p50), and SP-1, general transcription factors (GTF), tata binding 
protein (TBP) and host Pol II to the HIV 5’ LTR.  (B) Following initiation, the 
serine 5 residue of the Pol II CTD is phosphorylated.   Pol II processes past the 
transcription start site, forming the nascent RNA stem loop TAR, and pauses.  
Retention of this pause is mediated by binding of NELF and DSIF and closed 
chromatin structure.  NELF bridges the paused Pol II complex to the nucleosome 
through recruitment of factors that promote closed chromatin, including HDACs.  
(C)  Transcription elongation is mediated by HIV-1 Tat binding to the TAR RNA 
stem loop, which recruits the PTEF-b (CDK9 and cyclin T1).  CDK9 
phosphorylates the serine 2 residue of the Pol II CTD as well as NELF and DSIF.  
NELF is released from Pol II, and DSIF becomes activating and remains with 
processive Pol II.  Chromatin remodeling is mediated by HATs and SWI/SNF 
which facilitate the acetylation of lysine residues on H3 and H4 and ATP-
dependent chromatin remodeling.  (D)  A cohort of HIV+ elite controllers express 
elevated levels of the cyclin dependent kinase inhibitor p21.  p21 regulates HIV-1 
transcriptional elongation by inhibiting CDK9, and potentially induces a paused 
Pol II complex.  
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HIV Latency  
Following acute HIV infection, an individual will experience an 
asymptomatic period prior to progressing to AIDS, referred to as clinical latency.  
Although peripheral blood viral loads are low, HIV continues to replicate primarily 
in lymph nodes and gut associated lymphoid tissue (GALT) (Pantaleo et al., 
1993).  The length of clinical latency differs between individuals.  Factors that 
may contribute to the length of clinical latency include age, nutrition, stress, 
socio-economic status, and presence of co-infections (UNAIDS, 2012). Each of 
these factors can add to the overall strain on the patient’s compromised immune 
system, resulting in the depletion of CD4+ T cell populations and increase in 
plasma viral titers observed during progression to AIDS.   
In addition to clinical latency, a relatively rare subset of HIV-infected cells 
enters a state of transcriptional latency (Barber et al., 2006; Schiralli Lester and 
Henderson, 2012).   Transcriptional latency was discovered as a consequence of 
the efficacy of ART.  In spite of virtually undetectable viral loads in successful 
ART patients, upon treatment cessation, viral loads rebound (Finzi et al., 1997; 
Wong et al., 1997).   Virus recovered following rebound is more similar to founder 
viruses, suggesting that latency is established early in infection (Persaud et al., 
2000).  Putative reservoirs for latent HIV include central memory T cells and 
macrophages.  Both of these cell populations are relatively quiescent, which may 
contribute to repression of HIV-1 transcription.  Upon cellular activation, 
transcription resumes and infectious virions are produced (Wong et al., 1997).   
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Combination ART targets cell populations that support active virus replication but 
not latently infected cells, as evident in the fact that brief interruption of therapy 
results in rapid viral rebound, HIV spread, and T cell decline.  The effects of viral 
rebound underlie the importance of understanding mechanisms which maintain 
latency when developing potential strategies to eradicate the virus.   
Changes in histone acetylation and methylation within Nuc1 and Pol II 
pausing are associated control of HIV transcription, and have been implicated as 
key mechanisms in the establishment and maintenance of HIV transcriptional 
latency (Klatt et al., 2008; Natarajan et al., 2013; Schiralli Lester and Henderson, 
2012; Williams et al., 2006) (Fig. 3b).  Pol II pausing is maintained by factors 
such as DSIF and NELF, as well as post-translational modifications to 
nucleosome associated histones, including deacetylation and methylation, which 
favor retention of Nuc1 in a closed chromatin state.  NELF bridges paused Pol II 
with other inhibitory factors, such as nuclear co-repressor (NcoR) and HDACs, 
which favor repressive chromatin structure (Natarajan et al., 2013).  
Treatment strategies that attempt to purge latent reservoirs by activating 
HIV transcription with compounds that overcome transcriptional repressors, have 
garnered recent interest.  In particular, HDAC inhibitors (HDACi), such as 
suberoylanilide hydroxamic acid (SAHA) (Archin et al., 2009; Archin et al., 2012) 
and valproic acic (VPA) (Blazkova et al., 2012; Routy et al., 2012a; Routy et al., 
2012b), inhibit the function of histone deacetylases.  Initial studies suggested that 
treatment with HDACi could be used in a “kick and kill” strategy wherein HDACi 
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would be used to induce HIV transcription and increase efficacy of ART (Margolis 
and Hazuda, 2013).  However the data are conflicting as to whether treatment 
with HDACi can effectively induce transcription in latently infected cells, or impact 
the size of the latent reservoir (Rasmussen et al., 2013). 
 
HIV Elite Controllers 
Approximately 1% of HIV+ individuals are able to maintain viral loads 
below conventional detection in the absence of ART (Autran et al., 2011; Chun et 
al., 2013; Eyzaguirre et al., 2013; O'Connell et al., 2009).  No single phenotype 
has emerged, instead a number of immune correlates appear to limit replication 
in elite controllers (Brombin et al., 2013; Vigneault et al., 2011; Witwer et al., 
2012).  A subset of elite controllers share the HLA class I haplotype HLA B 57 
and 27 (O'Connell et al., 2010).  While enhanced CD8 killing function and 
preferentially targeting of Gag over Env are found in other cohorts of elite 
controllers (Buckheit et al., 2013; Buzon et al., 2013; Ferre et al., 2010; Turk et 
al., 2013).  Yet another subset of elite controllers has higher than average levels 
of the cyclin dependent kinase inhibitor p21 which limits HIV transcription (Fig. 
3d) (Buzon et al., 2011; Chen et al., 2011).   
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Macrophages 
General Biology of Macrophages 
Macrophages are phagocytes which take up extracellular materials, 
release inflammatory cytokines, chemokines, and anti-inflammatory mediators, 
and bridge the innate and adaptive immunity through their antigen presentation 
function (Gordon and Taylor, 2005; Strauss-Ayali et al., 2007).  Macrophages are 
primarily derived from monocytes which migrate into tissues where they mature 
into either macrophages or dendritic cells, however there is emerging evidence 
that some populations of macrophages are seeded early in development, 
continue to reside within the tissue, and repopulate this microenvironment 
independent of circulating monocytes (Ginhoux et al., 2010; Schulz et al., 2012).   
Pattern recognition receptors (PRR) on the macrophage cell surface 
recognize conserved motifs on pathogens, including the lipopolysaccharide 
(LPS) coating on gram negative bacterial, viral RNA, and peptidoglycan. PRR’s 
may also recognize self-antigens or debris from cellular damage, leading to their 
role in the auto-immune responses (Akira and Takeda, 2004; Takeda and Akira, 
2004).  The toll-like family of receptors (TLR) is one of the most well 
characterized PRR, consisting of 10 human TLRs that share a leucine rich 
extracellular domain and an intracellular Toll/Interleukin-1 receptor (TIR) domain.  
Each TLR triggers macrophage responses to a distinct set of pathogen products.  
TLR2, in combination with either TLR1 or 6, recognizes bacterial peptidoglycans 
and yeast zymosan, TLR3 recognizes viral double stranded RNA, and TLR 9 
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recognizes DNA.  TLR4, with CD14 and MD-2, recognizes bacterial LPS (Akira 
and Takeda, 2004; Takeda and Akira, 2004).   Due to the potent induction of 
inflammatory cytokines induced by LPS, this bacterial product is commonly used 
in vitro to study mechanisms that more generically regulate inflammatory 
cytokine production.  The preliminary step in TLR4 activation by LPS is the 
binding of LPS to CD14 which triggers a downstream signaling cascade through 
TLR4 that induces the expression of a number of inflammatory cytokines.  TLR4 
signals through two different pathways, that require either the MyD88 adapter 
protein and results in NF-κB activation, or TRIF and TRAM, which activate IRF3 
and 7 as well as NF-κB, and induce the expression of type I interferons (Akira 
and Takeda, 2004; Takeda and Akira, 2004).   
In addition to recognition of foreign molecules, macrophages also function 
in the recognition and removal of apoptotic cells (Ravichandran, 2011).  
Clearance of apoptotic cells is an important inflammatory control mechanism 
mediated by macrophages.  A number of macrophage receptors recognize 
molecules which have flipped to the outer leaflet of the plasma membrane 
following apoptosis, including phosphatydlyserine (PS) and oxidized low density 
lipoproteins (oxLDL).  The PS receptor directly binds to flipped PS, while the 
Tyro/Axl/Mer family of receptors and T cell immunoglobulin mucin domain-1 
(TIM-1) recognize molecules, extra-cellular growth arrest-specific 6 (Gas6) and 
milk fat globule-EGF 8 (MFG-E8), bound to externalized PS (Lemke and Burstyn-
Cohen, 2010).  oxLDL are recognized by scavenger receptors, including 
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scavenger receptor A (SRA) and CD36 (thrombospondin receptor).  Upon 
binding, apoptotic cells are phagocytosed and cleared, preventing inflammation 
in response to dead cells (Ravichandran, 2011). 
 
Macrophages and Inflammation 
Macrophages are classically considered mediators of inflammation, 
secreting inflammatory cytokines such as interleukin (IL)-12 (Kobayashi et al., 
2011; Trinchieri, 2003; Zhou et al., 2004), tumor necrosis factor alpha (TNFα), 
and IL-6, which activate and recruit additional immune cells to combat infection 
and tissue damage (Cohen and Mosser, 2013; Murray and Wynn, 2011b).  As 
important as it is to initiate a proper immune response, it is also necessary to 
resolve inflammation.  Persistent inflammation results in inflammatory disorders 
and autoimmunity.  In addition to autocrine feedback loops which terminate 
expression of inflammatory cytokines, macrophages express anti-inflammatory 
mediators such as IL-10 , transforming growth factor β (TGFβ), and arginase-1 
(Arg-1), that inhibit inflammation and aid in tissue repair following an immune 
response (Cohen and Mosser, 2013; Murray and Wynn, 2011b).  
Common macrophage markers for polarized macrophage function include 
inducible nitric oxide synthetase (iNOS) and Arg-1 (Fig. 4), which utilize the same 
substrate (Chang et al., 1998; Gobert and Wilson, 2012; Mosser, 2003; Sharda 
et al., 2011; Van den Bossche et al., 2012).  iNOS uses the L-arginine substrate 
to produce nitric oxide (NO), which is beneficial in killing intra- and extracellular 
 
20 
 
pathogens, but leads to the formation of reactive oxygen species which cause 
damage to surrounding cells and tissue.  Arg-1 converts L-arginine to ornithine, 
which upregulates extracellular matrix synthesis through the production of 
polyamines and proline.  Although, the Arg-1-iNOS axis is classically used to 
delineate inflammatory and anti-inflammatory macrophage subsets (Cassetta et 
al., 2011; Cohen and Mosser, 2013; Gordon and Taylor, 2005); this is probably 
an oversimplification of macrophage function.  Macrophages concurrently 
produce both enzymes, indicating a spectrum of macrophage functional 
phenotypes rather than polarization into two distinct terminally differentiated 
populations (Mattila et al., 2013).   
  
 
  
 
21 
 
 
 
Figure 4.  Arginase and iNOS axis.   Arginine and iNOS compete for the same 
substrate, L-arginine.  iNOS expression results in the production of nitric oxide 
and citruline, which contributes to pathogen killing mechanisms, but results in 
bystander tissue injury .  Arginase expression results in the production of proline 
and polyamines which mediate repair mechanisms through synthesis of 
extracellular matrix. 
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Tissue-Resident Macrophages 
Tissue-resident macrophages are a heterogenous population of long lived 
macrophages within the tissue micro-environment (Fig. 5).  Tissue-resident 
macrophages function in immune surveillance, and include specialized 
macrophages such as: Kupffer cells in the liver, alveolar macrophages in the 
lung, bone osteoclasts, and microglia in the central nervous system (Davies et 
al., 2013; Murray and Wynn, 2011).  The complex combination of growth factors, 
cytokines, matrix proteins, organ specific cell types and stroma, as well as long 
term residence with hypoxic tissue microenvironments influences the function 
and phenotype of the tissue-resident macrophage.  CD16lo (FCγRIII) monocytes, 
and their mouse homologue lymphocyte antigen 6Clo (Ly6C) monocytes, appear 
to be less likely to mature into inflammatory macrophages; suggesting that a 
subset of circulating monocytes may be responsible for reseeding tissue-resident 
macrophage populations (Crowe et al., 2003; Gama et al., 2012; Hanna et al., 
2011; Hanna et al., 2012).  In vitro conditions to mature and polarize 
macrophages into subsets have failed to recapitulate a tissue-resident 
macrophage, which may reflect the influence of cell-cell interaction and tissue 
organization in macrophage phenotype (Martinez et al., 2006; Murray and Wynn, 
2011a; Scotton et al., 2005). 
There is emerging evidence that challenges the paradigm that all 
macrophages are derived from circulating monocytes.  A portion of tissue 
macrophages are derived from the embryonic yolk sac, rather than bone-marrow, 
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progenitors and are self-renewing (Ginhoux et al., 2010; Hashimoto et al., 2013; 
Schulz et al., 2012).  Furthermore, following parabiosis, most tissue 
macrophages retain host specificity; and only a fraction of tissue macrophages 
exhibit nonhost chimerism (Ginhoux et al., 2010).  These observations provide 
further insight into why in vitro polarization of circulating monocytes may not be 
sufficient to create a tissue-resident macrophage phenotype. 
 
Tissue-resident macrophages function to maintain homeostasis within the 
normal tissue environment (Murray and Wynn, 2011b).  It is important that an 
activation threshold exists which prevents aberrant inflammation; this is 
particularly important for macrophages at mucosal membrane sites, where cells 
are in constant contact with pathogens and benign foreign substances, 
contributing to tolerance to commensal bacteria and food antigens.  Once this 
threshold is overcome, tissue-resident macrophages secrete cytokines and 
chemokines which recruit circulating monocytes that further amplify the immune 
response. 
  
Tonsil Macrophages 
Human palatine tonsils are paired mucosa-associated secondary lymphoid 
tissue found at the entry point to both the digestive and respiratory systems.   As 
lymph node tissue, tonsils contain large aggregates of B and T lymphocytes, but 
they also contain interstitial epithelial tissue that houses T cells, B cells, dendritic 
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cells, Langerhans cells, and resident macrophages (Glushakova et al., 1995; 
Grivel and Margolis, 2009; Kawaguchi et al., 1988; Perry and Whyte, 1998; Stent 
et al., 2002; Watanabe et al., 1974; Willson et al., 1976a; Willson et al., 1976b).  
Tonsillar macrophages are an easily accessible source for human tissue-resident 
macrophages.  Macrophages from tonsils adhere to tissue culture plastic in a 
manner similar to monocyte derived macrophages (MDM), and 64-82% of these 
adherent cells are phagocytes capable of uptake of fluorescently labeled beads 
and apoptotic cells to a degree comparable of that of MDM (Stent et al., 2002).  
 
Microglia  
 Microglia are specialized tissue-resident macrophages in the central 
nervous system (CNS), which differ from other brain macrophages (perivascular 
and meningeal macrophages) by their extensive branching morphology, lack of 
scavenger receptors, and greater proliferative activity (Gehrmann et al., 1995; 
Ransohoff and Perry, 2009; Saijo and Glass, 2011).  Fate mapping studies have 
indicated that microglial populations are seeded early in development from yolk 
sac progenitors (Ginhoux et al., 2010).  While roughly 30% of tissue-resident 
macrophages were reconstituted by donor cells following parabiosis, only 5% of 
microglia had donor-chimerism; suggesting even less dependence on circulating 
monocytes to seed microglia populations.  The role of microglia in CNS 
inflammation is thought to be a double-edged sword.  While important in 
mounting an effective immune response in the CNS, chronic activation and loss 
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of inflammatory control by of microglia results in neuro-inflammatory disorders 
such as Alzheimer’s, multiple sclerosis (MS), and HIV-associated dementia 
(HAD) (Block et al., 2007; Ghafouri et al., 2006; Gomes-Leal, 2012; Gonzalez-
Scarano and Martin-Garcia, 2005; Yadav and Collman, 2009).   
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Figure 5.  Tissue-resident macrophages.    Tissue-resident macrophages are 
long lived macrophages within the tissue microenvironment which possess 
specialized functions specific to a particular microenvironment, such as the bone 
resorption function of osteoclasts, red blood cell clearance by red pulp splenic 
macrophages, and food antigen tolerance by intestinal macrophages. 
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In vitro polarization of macrophages  
Macrophages subsets have been defined using murine model systems, 
and characterized into functional subsets based primarily on cytokine production 
(Cassetta et al., 2011; Cassol et al., 2009; Lawrence and Natoli, 2011; Mantovani 
et al., 2002; Martinez et al., 2006; Murray and Wynn, 2011a).  Murine bone 
marrow derived macrophages have been polarized into the different subsets by 
altering in vitro culture conditions.  Inflammatory stimuli, including inflammatory 
cytokines (interferon gamma (IFNγ) or TNFα, LPS, or combinations of these 
factors, are used to polarize inflammatory, classically activated macrophages 
(CM).  CM are functionally characterized by induction of inflammatory cytokine 
expression, usually TNFα or IL-12, or NO production, and “fried egg” 
morphology.  Conditions to generate alternatively activated macrophages (AM) 
are even more varied (Gordon, 2003; Mantovani et al., 2002; Mosser, 2003).  
The most commonly described AM replicate Th2 inflammatory response 
conditions and are polarized with IL-4.  A second type of AM is induced by IL-10 
treatment; while a third AM subset is generated using immune complexes and 
LPS/IL-1β.   Each of these AM conditions produces a slightly different cytokine 
profile, but collectively they all express lower levels of inflammatory cytokines, 
different combinations and amounts of anti-inflammatory factors, including (IL-10, 
Fizz1, Arg-1, and YM1), and have a spindle shaped morphology (Martinez et al., 
2006). 
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Macrophages treated with polarizing conditions have plasticity and do not 
have fixed phenotypes, presumably to allow for appropriate responses to 
changes in microenvironment such as new infections or tissue remodeling 
(Mantovani et al., 2013).  For example, cells polarized in the presence of IL-4, to 
induce AM will produce CM inflammatory cytokines following LPS treatment.  
However, LPS polarized CM continue to produce CM inflammatory cytokines 
following IL-4 stimulation (Garrett et al., 2008).  It may be that the strength of the 
signal (LPS v IL-4) determines the plasticity of the macrophage phenotype.  
Peripheral blood monocytes are the most accessible population of human 
monocytes, therefore these cells are frequently matured and polarized in vitro to 
study human macrophage function.  However, human macrophages do not 
express Fizz1 and YM1 which are often used to phenotype murine AM (Martinez 
et al., 2006).  The ability of polarized human macrophages to produce Arg-1 or 
iNOS has also been highly debated.  It is clear that factors used to polarize 
murine macrophages do not consistently induce expression of these factors by 
human macrophages in vitro; however there is evidence that human 
macrophages are competent to produce Arg-1 and iNOS.  Peripheral monocytes 
isolated following trauma injury and surgery (Ochoa et al., 2001; Tsuei et al., 
2001), and macrophages found in tuberculosis granulomas express Arg-1 
(Mattila et al., 2013; Pessanha et al., 2012).  Functional outcomes of human 
macrophages may be more complex in vivo, and in vitro polarization conditions 
may exaggerate or mask the true spectrum of these outcomes. 
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Inflammation and HIV/AIDS 
 The severe immunodeficiency associated with AIDS is characterized by 
depletion of CD4+ T cells; however chronic HIV infection also presents wide-
spread immune dysregulation, as indicated by elevated levels of inflammatory 
cytokines and increased numbers of activated T cells (Chang et al., 2013; Marin 
et al., 2009).  One major cause of chronic HIV-associated inflammation is the 
breakdown of the gut mucosal barrier, leading to translocation of bacterial 
products, including soluble LPS (Marchetti et al., 2013).  Additionally, HIV targets 
molecular mechanisms that control inflammation thereby preventing proper 
resolution of inflammatory responses, leading to increased expression of 
inflammatory mediators and activated immune cells (Kalantari et al., 2008; 
Kedzierska et al., 2002; Lee et al., 2004; Perez-Bercoff et al., 2003; Renga et al., 
2012).  Overall excess inflammation exacerbates HIV infection by increasing the 
number of available cells that can be targeted for infection, while inflammatory 
cytokines induce HIV transcription.   
While ART effectively targets steps in the viral life cycle, it does not 
address immune dysfunction associated with chronic HIV infection, leading to the 
continued prevalence of co-infections, metabolic disorders, and neuro-
inflammation associated with AIDS. 
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HIV and Macrophages 
Macrophages possess multiple intrinsic mechanisms which control 
inflammation and limit HIV infection, including Fcgamma Receptor (FCγR), 
nuclear receptors, and the receptor d’origine Natais (RON) receptor tyrosine 
kinase.  HIV targets these inhibitory mechanisms facilitating more efficient 
replication.  
FCγRs, which are required for recognition and phagocytosis of IgG-
opsinized particles and pathogens, limit inflammation by inhibiting the expression 
of pro-inflammatory cytokines such as IL-12 and inducing the production of anti-
inflammatory cytokines such as IL-10 (Nimmerjahn and Ravetch, 2008). 
Crosslinking FCγRs inhibits HIV replication in monocyte derived macrophages 
(Perez-Bercoff et al., 2003), and HIV-infected macrophages have impaired FCγR 
mediated phagocytic ability (Kedzierska et al., 2002). Furthermore, 
polymorphisms in FCγRIIA have been associated with more rapid disease 
progression, suggesting a protective role of certain FCγR genotypes (Forthal et 
al., 2007).  
Nuclear receptors inhibit inflammatory responses by regulating the 
transcription of inflammatory mediators and HIV (Glass and Saijo, 2010).  
Nuclear receptors, such as peroxisome proliferator-activated receptor (PPARγ) 
and liver X protein (LXR) inhibit HIV transcription through trans-repression, which 
diminishes NF-κB recruitment to the HIV LTR and facilitates the assembly of the 
NCoR1 complex (Hanley and Viglianti, 2011). HIV-infected patients have been 
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reported to have altered expression of nuclear receptors (Renga et al., 2012), 
suggesting additional mechanisms by which HIV infection can promote ectopic 
inflammation.  
 
RON receptor tyrosine kinase 
Expression of RON 
RON is a receptor tyrosine kinase (RTK) related to the MET proto-
oncogene family of RTKs (Correll et al., 2004).  RON has also been referred to in 
the literature as macrophage stimulating 1 receptor (MST1R) and hepatocyte 
growth factor-like protein receptor (HGFLR) (Bezerra et al., 1998; Gorlatova et 
al., 2011).   Human RON was first cloned from a human foreskin keratinocyte cell 
line cDNA library (Ronsin et al., 1993).  The mouse homologue of RON, stem cell 
tyrosine kinase (STK), was cloned from murine hematopoietic cells (hereafter 
referred to as mRON) (Iwama et al., 1994).  mRON is expressed on murine 
epithelial cells, granulocytes, and tissue-resident macrophages including: 
peritoneal macrophages, Kupffer cells, microglia, dermal macrophages, and 
osteoclasts (Correll et al., 2004; Dai et al., 2002; Lee et al., 2004; Nanney et al., 
1998; Stuart et al., 2011; Wang et al., 2000).  Expression of RON has not been 
observed in murine bone-marrow derived macrophages and splenic red pulp 
macrophages (Correll et al., 2004).   
Expression patterns of RON on human tissue-resident macrophages have 
been limited due to challenges in obtaining human tissues and isolating 
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macrophages.  Expression of RON has been observed in human CNS 
macrophage populations and tonsil derived macrophages, but not in human 
peripheral blood monocytes or MDM (Lee et al., 2004).  Standard conditions to 
human mature MDM, including treatment with phorbol myristate acetate (PMA) 
and culture on tissue culture treated plastic, do not induce RON expression, nor 
do conditions traditionally used to polarize CM or AM (Appendix A). 
 
RON isoforms 
At least 8 naturally occurring isoforms of RON exist, due primarily to 
alternative mRNA splicing (Lu et al., 2007; Yao et al., 2013).  The resulting RON 
isoforms contain various deletions within the extracellular domain, which result in 
MSP-independent or constitutive RON signaling (Yao et al., 2013).  RON 
isoforms, having deletions within the ligand binding or juxtamembrane domains 
have been identified in a number of epithelial cell tumors including breast, lung, 
and colon tumors (Bardella et al., 2004; Lu et al., 2007; Ma et al., 2010).  The 
short form of RON, a truncated isoform missing the majority of the extracellular 
domain, is the product of a second promoter upstream from the primary RON 
promoter.  The mechanism leading to initiation from the alternate promoter is 
unclear, but may be due to DNA methylation patterns in the two RON promoters 
(Del Gatto et al., 1995).   
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General Structure of RON and MSP 
RON is a heterodimer consisting of an 40 kDa β chain that has 
extracelluar and intracellular signaling domains, and an extracellular 140 kDa α 
chain that forms a disulfide linkage with the β chain to form the ligand binding site 
(Fig. 6) (Angeloni et al., 2004; Chao et al., 2012; Yao et al., 2013).  RON is 
produced as a single chain precursor protein, pro-RON, which undergoes furin 
mediated cleavage in the endoplasmic reticulum to form the mature RON 
heterodimer (Angeloni et al., 2000).  
RON ligand is macrophage stimulating protein (MSP), an 80 kDa serum 
protein produced by the liver (Brunelleschi et al., 2001; Kawaguchi et al., 2009).  
MSP is also known as macrophage stimulating 1 (MST1) (Gorlatova et al., 2011) 
and hepatocyte growth factor-like protein (HGFL) (Bezerra et al., 1998).  MSP is 
secreted by the liver as pro-MSP, and extracellular proteases cleave the enzyme 
to produce the biologically active form (Yao et al., 2013).   The RON β chain 
contains a semaphorin (SEMA) domain, which recognizes and binds MSP.  A 
single MSP molecule binds the SEMA domains of two RON receptors, resulting 
in receptor dimerization (Angeloni et al., 2004; Chao et al., 2012).   
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Figure 6.  Structure of RON receptor tyrosine kinase.  RON is a heterodimeric 
receptor with an α chain bound to the β chain by a di-sulfide bond.  The α and β 
chains form the binding site for MSP, RON ligand.  The β chain has both 
extracellular and intracellular signaling domains, with functional tyrosine residues 
in the kinase and docking domains.   
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RON signaling 
RON signals in both ligand-dependent and independent manners (Ma et 
al., 2010; Wei et al., 2005a; Wei et al., 2005b).  Signaling by RON is mediated by 
its kinase domain which contains three tyrosine residues: 1101, 1238, and 1239.  
Tyrosines 1238 and 1239 contain the activation loop which mediates receptor 
autophosphorylation of docking site tyrosines at positions 1353 and 1360 (Fig. 7) 
(Danilkovitch and Leonard, 1999; Wei et al., 2005b).  Phosphorylation of the 
docking site tyrosines recruits SH2 containing molecules, Gab1 and Grb2 which 
trigger downstream activation of PI3K and MAPK pathways (Chen et al., 1998; Ni 
et al., 2007).  RON signaling induces cell spreading and chemotaxis in epithelial 
cells and macrophages (Wang et al., 2002).   RON also induces C3 mediated 
engulfment of erythrocytes (Lutz and Correll, 2003) and regulation of 
inflammatory (Liu et al., 1999; Morrison et al., 2004; Nikolaidis et al., 2010; Ray 
et al., 2010; Wilson et al., 2008) and anti-inflammatory mediators (Morrison and 
Correll, 2002; Sharda et al., 2011) which regulate homeostasis of inflammation in 
macrophages .   
In addition to the RON homodimer signaling, RON is capable of forming 
heterodimers with other RTKs and oncogenic viruses (Fig. 7d) (Follenzi et al., 
2000; Ni et al., 2007; Yao et al., 2013).  RON can form heterodimers with MET, 
ILGFR1 and EGFR resulting in enhanced tumorigenic activity by these receptors.  
The Epstein Barr virus and Jaagsiekte sheep retrovirus contain viral proteins that 
bind and signal through RON, resulting in transformed cells.  In mice, Friend 
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virus binds to short form RON and induces epo-independent erythropoiesis 
resulting in virus-induced erythroleukemia (Fig. 7e) (Bardella et al., 2004). 
MSP-independent RON activity is also observed when RON is stably 
overexpressed in HEK 293 cells (Wei et al., 2005a; Wei et al., 2005b) and the 
human pro-monocytic cell line U937 (Fig. 7b) (Klatt et al., 2008; Lee et al., 2004).  
Using mutants of the functional tyrosine residues in the cytoplasmic tail of RON, 
it was determined that MSP-independent activation of MAPK kinase pathways is 
independent of the two docking site tyrosines, while the kinase activity of RON is 
integral to MSP-dependent and independent activity.   
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Figure 7.  RON signaling.  (A)  MSP dependent RON signaling induces 
dimerization and autophosphorylation of docking site by the kinase domain.  
Activation of RON induces PI3K and Erk pathways mediated by binding of Grb2 
to the docking site.  (B)  RON MSP-independent signaling results in activation of 
Erk and PI3K, but docking site tyrosines are not crucial to induction of the MSP-
independent signaling.  (C)  Alternate isoforms of RON are highly expressed in 
some tumors.  Residues within the extracellular domain are mutated or absent, 
resulting in constitutive signaling.  (D)  RON can form heterodimers with other 
receptor tyrosine kinases, including MET, EGFR, and ILGFR1.  (E)  Short form 
RON is naturally occurring isoform of RON lacking the extracellular domain.  The 
Friend leukemia virus can bind short form RON and induce epo-independent 
erythropoiesis through activation of the JAK-Stat3 pathway. 
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RON and inflammation 
 A key function of RON in macrophages is to regulate inflammation in 
tissue microenvironments.  RON inhibits expression of LPS and IFNγ inducible 
inflammatory mediators including IL-12 p40 (Morrison et al., 2004; Wilson et al., 
2008), iNOS (Chen et al., 1998), and TNFα (Nikolaidis et al., 2010) in mouse 
peritoneal macrophages, by inducing expression of SOS1 and 3 which target 
Stat 1, and prevention of IκB degradation (Fig.8a).  RON activates genes that are 
involved in tissue repair mechanisms and inhibit further immune activation such 
as IL-1RA, SRA, and Arg-1 (Morrison and Correll, 2002; Sharda et al., 2011).  
RON induces expression of Arg-1 through Stat6 dependent induction of Ap-1 
(Fig. 8b).  RON also down-regulates IFNγ induced MHC II expression on 
peritoneal macrophages (Wilson et al., 2008).  Additionally, RON induces the 
expression of small heterodimer partner 1 (SHP-1), a negative regulator of TLR 4 
signaling, which acts as a negative feedback mechanism (Yuk et al., 2011). RON 
acts as critical modulator of inflammation, by down-regulating pro-inflammatory 
and antigen presenting functions of tissue macrophages, while up-regulating 
factors that resolve inflammation and mediate tissue repair.  
 Mouse knockout models for RON and MSP have been established.  RON 
knockout mice have an exaggerated response to endotoxin challenge 
characterized by elevated inflammation, cytokine production, tissue damage, and 
mortality (Correll et al., 1997; Stuart et al., 2011). Furthermore, RON knockout 
mice are prone to inducible organ specific inflammatory diseases including 
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experimental allergic encephalitis (Tsutsui et al., 2005), bacterial peritonitis 
(Caldwell et al., 2008), and acute lung injury (McDowell et al., 2002; Nikolaidis et 
al., 2011).  RON knockouts are more susceptible to Listeria monocytogenes 
infection (Lutz et al., 2002), suggesting compromised cell-mediated immunity.  
MSP knockout mice have no observable phenotype or defect in wound healing 
following skin wounding (Kawaguchi et al., 2009), suggesting a role for RON 
MSP-independent signaling or the existence other ligands which activate RON. 
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Figure 8.  RON signaling inhibits inflammation and HIV while inducing 
repair mechanisms.  (A)  RON signaling inhibits LPS and IFNγ induced 
expression of iNOS, IL-12 p40, and TNFα.  RON induces the expression of 
SOS1 and 3 which target IFNγ induced Stat 1 expression, and prevents IκB 
degradation resulting in an inhibition of NF-κB.  (B)  RON induces expression of 
Arg-1 through Stat6 dependent induction of Ap-1.  (C)  RON inhibits HIV through 
inhibition of NF-κB binding to the HIV LTR, retention of NELF, and inhibition of 
Nuc1 remodeling. 
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RON and HIV 
Previous work from our laboratory has shown that RON represses HIV 
transcription, both in the U937 monocytic cell line and human primary MDM 
stably expressing RON (Klatt et al., 2008; Lee et al., 2004).  Inhibition of HIV 
transcription by RON requires both the docking site tyrosines and kinase domain 
(Klatt et al., 2008).  Expression of RON inhibits HIV transcription through multiple 
mechanisms, including transcriptional initiation, elongation, and chromatin 
remodeling (Fig. 8c) (Klatt et al., 2008).  Overexpression of RON inhibits NF-κB 
activity, decreases IκB-α degradation, and inhibits binding of NF-κB p65 to the 
HIV LTR; while CEBP/β activity and Pol II recruitment are unaffected. RON also 
mediates the establishment of a paused Pol II complex, favoring Pol II 
association with NELF and DSIF at the HIV LTR.  Furthermore, RON promotes 
heterochromatin formation, as indicated by decreased histone acetylation and 
reduced nucleosome accessibility at Nuc1 on the HIV LTR.  RON-mediated 
repression of HIV transcription is partly relieved by treatment with IL-6 and TNFα.  
Cytokine treatment partially relieves the block on NF-κB p65 recruitment and Pol 
II processivity, as observed by Pol II occupancy downstream of the transcription 
start site.  However, in spite of relief of certain inhibitory mechanisms, NELF 
binding remains elevated at the HIV LTR in cytokine treated RON-expressing 
cells.  The ability of RON signaling to inhibit HIV transcription elongation may 
contribute to the establishment and maintenance of HIV latency in macrophages.   
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RON expression is down regulated during HIV infection.  RON is directly 
targeted for ubiquitin mediated degradation by HIV Tat following 24h treatment 
with recombinant Tat (Kalantari et al., 2008).  Expression was unaffected by 
infection with HIV expressing a missense and nonfunctional Tat.  Expression of 
RON is reduced in post-autopsy brain tissue of patients with HIV-associated 
encephalitis (Lee et al., 2004).  Together these in vitro studies and clinical 
observations indicate that a loss of RON expression correlates with HIV infection 
and disease progression. 
 
HIV-associated CNS disease 
Clinical significance 
 The central nervous system is a primary target of HIV, with evidence of 
infection in brain macrophages and microglia within two weeks after initial 
transmission of the virus (Davis et al., 1992; Palmer et al., 1994). Nearly 60% of 
individuals infected with HIV-1 experience associated neural disorders, which 
include loss of short term memory, personality changes, and loss of 
computational and cognitive functions (Ghafouri et al., 2006).   Following 
autopsy, 90% of HIV-infected individuals have evidence of CNS lesions (Block et 
al., 2007).  Use of ART has decreased the severity of AIDS-associated CNS 
diseases, resulting in fewer cases of HIV-associated dementia (HAD) but 
continued incidence of HIV-associated neurological disorders (HAND) remains 
prevalent (Ghafouri et al., 2006; Gonzalez-Scarano and Martin-Garcia, 2005; 
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Heaton et al., 2011; Moore et al., 2011; Robertson et al., 2008). The inability of 
HAART to decrease CNS disease may reflect the fact that current treatments 
target viral replication but not immune dysfunction associated with HIV infection, 
and also the inability for effective drug penetrance into the CNS (Shiramizu et al., 
2012).   Infection of cells within the CNS establishes potential long-term HIV 
reservoirs, and triggers inappropriate inflammation and tissue damage.   
 
Inflammatory responses and their role in HIV-associated CNS disease 
Following HIV and SIV infection in the brain, pro-inflammatory cytokines 
and cytotoxic factors, such as TNFα, IL-12, IL-6, IFNβ, IL-1β, and NO, are 
secreted by perivascular macrophages and microglia (Witwer et al., 2009; Yadav 
and Collman, 2009; Zink et al., 1999). Release of these factors promotes 
neuronal cell death, results in the break-down of the blood brain barrier, and 
recruits circulating immune cells to perpetuate the inflammatory response 
(Eugenin et al., 2011; Williams and Burdo, 2012; Zaritsky et al., 2012). Excessive 
damage to neurons further activates macrophages and microglia, which release 
additional cytotoxic factors.  Prolonged HIV infection and excessive inflammation 
contribute to enhanced HIV replication and HIV-associated CNS disease.  The 
mechanisms that initiate and sustain this inflammation are poorly understood. 
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Models to study HIV-associated CNS disease 
 In spite of the importance of CNS infection in HIV/AIDS, our knowledge of 
mechanisms that initiate and maintain HIV-associated CNS disease is limited by 
available models.  The presence of HIV-infected CNS macrophages and 
microglia within two weeks after infection was discovered following hospital 
acquired infections and non-AIDS related mortalities (Davis et al., 1992; Palmer 
et al., 1994); however this is not a feasible scheme to study early events of HIV 
infection in the CNS.   Post-autopsy brain tissue from end stage HIV+ patients are 
studied, but sampling during infection is prohibitive.   
SIV infection in non-human primates has been used as a tractable model 
to observe the establishment and maintenance of CNS infections.  One such 
model has been developed by Dr. Clements and colleagues at Johns Hopkins 
University (Fig. 9).  This pigtailed macaque model has been well characterized.  
Macaques develop similar symptoms in approximately 80 days to the HIV-
associated disease which takes years to develop in humans (Clements et al., 
2008; Graham et al., 2011).  Neurodisorders associated with this model include a 
decrease in general motor activity, delayed reaction time, and latency in 
performing a bi-manual motor task (Weed et al., 2003).  Additionally, SIV-infected 
macaques treated with a combined ART regime of two reverse transcriptase 
inhibitors had below limit of detection SIV RNA in plasma and CSF, while latent 
CD4+ T cells were detected in spleen and lymph nodes (Clements et al., 2011; 
Dinoso et al., 2009; Graham et al., 2011). 
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Pigtail macaques are infected with two strains of SIV, the 
immunosuppressive swarm SIV/Delta B670 and the neurovirulent strain 
SIV17E/Fr.  SIV/Delta B670 was derived from a lymph node of a rhesus 
macaque infected with SIVsmm (Babas et al., 2006).  SIV/Delta B670 is a swarm 
of at least 20 envelope genotypes containg both neuro-virulent and non-neuro-
virulent clones (Babas et al., 2006).  Infection of macaques with the SIV/Delta 
B670 swarm results in full spectrum of AIDS related inflammatory dysfunctions 
including, immunosuppression, pneumonia, opportunistic infections, and 
encephalitis.  SIV17E/Fr was created by replacing the envelope, Nef and 3’ LTR 
regions of SIVmac239 (which is non-neurovirulent) with those of SIV/17E-Br 
(which is neurovirulent) (Babas et al., 2006).  SIV17E/Fr efficiently targets the 
CNS.   When inoculated together, the two viruses produce a consistent SIV-
associated CNS disease model, in which 90% of SIV-infected animals have 
evidence of inflammatory lesions, perivascular cuffs of macrophages, in the brain 
(Clements et al., 2011; Clements et al., 2008).   
Following inoculation, at 4 days post infection, SIV RNA is found in the 
brain tissue and plasma of SIV-infected macaques, accompanied by elevated 
CNS expression of TNFα, IL-6, IL-10, and IFN-β (Dudaronek et al., 2007; 
Ravimohan et al., 2010; Witwer et al., 2009).  The acute infection persists until 
day 14.  From days 14 to 42 SIV-infected macaques undergo an asymptomatic 
phase.  Viral RNA in the CNS and CSF is markedly decreased from levels during 
the acute infection, and IFN-β is no longer detected in the CNS.  At 
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approximately at day 42, SIV infected macaques begin to present CNS disease 
symptoms and exhibit changes in the expression cytokines and 
immunomodulatory molecules including; IL-12 p40,TNFα, IFNβ IL6, IL-10, MHC 
class II, MCP-1 (Witwer et al., 2009). 
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Figure 9.  Clements model to study SIV-associated CNS disease. (Clements 
et al., 2008).  Pigtail macaques are infected at day 0 and develop and acute 
infection characterized by elevated IFNβ and SIV RNA in the brain.  Following 
day 10, IFNβ and SIV RNA expression decreases, leading to the asymptomatic 
phase of infection.  However, around day 42, animals transition from 
asymptomatic to chronic infection, when SIV RNA and IFNβ are detectable.  By 
day 84, 90% of SIV infected macaques exhibit inflammatory lesions of 
macrophage cuffs. 
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Hypothesis and Goals of this study 
Data from our laboratory indicate that reduced RON expression correlates 
with incidence of HIV-associated encephalitis (Lee et al., 2004).  Endogenous 
targets of RON are dysregulated during the course of infection, contributing to 
the observed neuropathology.  Furthermore, our lab has demonstrated that RON 
inhibits HIV transcription by induction of a proximal promoter pausing of POLII 
and a repression of processive full length transcripts (Klatt et al., 2008; Lee et al., 
2004).  
 Utilizing the macaque model we tested the correlation between RON 
expression and SIV-associated CNS disease.  We determined that RON 
expression was dysreguated in the CNS during SIV infection and was expressed 
significantly less following chronic infection.  RON expression negatively 
correlated with inflammatory disease progression; as determined by elevated 
expression of IL-12 p40 and TNFα, diminished expression of Arg-1, and the 
presence of inflammatory lesions.  Furthermore RON expression negatively 
correlated with SIV viral load in the brain.   
 Human tonsil-derived tissue-resident macrophages were used to validate 
the correlations observed in the macaque model, and build upon these findings 
to establish a mechanism by which RON and HIV interact.  Furthermore, HIV 
infection of tissue-resident macrophages results in lower RON expression. 
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 Together these finding lead us to hypothesize that reduced activity of RON 
results in elevated expression of targeted inflammatory genes, thereby 
contributing to AIDS-associated CNS inflammation.   
 In addition to RON, other intrinsic cellular mechanisms limit HIV 
transcription, one such mechanism is the cyclin dependent kinase inhibitor p21; 
which is expressed highly in a cohort of HIV+ elite controllers (Chen et al., 2011).  
Elite controller T cells, infected with HIV in vitro, express lower levels of HIV 
mRNA.  p21 inhibits CDK9 (Chen et al., 2011), and potentially prevents the 
phosphorylation of NELF and Pol II, which would promote HIV transcriptional 
elongation .   
 Using a lentiviral construct expressing p21, we were able to determine if in 
vitro overexpression of p21 inhibits HIV transcription in human CD4+ T cells.  
Preliminary studies indicate that p21 overexpression limits HIV transcription, and 
further studies are required to conclusively determine the mechanism of the 
inhibition.  CD4+ T cells, from HIV+ elite controllers and seronegative controls, 
were infected with HIV in vitro.  Chromatin was isolated, and chromatin 
immunoprecipitation was performed to test differences in transcription factor 
binding to the HIV LTR.  Preliminary studies indicate that Pol II is recruited to the 
HIV LTR in both HIV+ elite controller and seronegative control T cells.  There is a 
trend of elevated NELF binding in elite controller samples. 
 
52 
 
 Together these preliminary studies support the hypothesis that elevated 
p21 expression in HIV+ elite controllers inhibits HIV transcription elongation 
through induction of polymerase pausing.   
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MATERIALS AND METHODS 
 
SIV-associated CNS disease model 
Archived mRNA samples were obtained from Clements lab at Johns 
Hopkins University School of Medicine.  Pigtail macaques were infected with SIV 
in accordance with federal guidelines and institutional policies at Johns Hopkins 
University School of Medicine, as previously described (Zink et al., 1999).  
Macaques were infected with two SIV variants:  an immune-suppressive variant 
(SIV/Delta B670) and a neuro-virulent variant (SIV/17E-Fr).  Within three months 
of SIV infection, 90% of infected pigtail macaques develop inflammatory lesions, 
providing a consistent, accelerated model to study the dynamic events 
contributing to SIV-associated CNS disease.  CNS disease lesion score was 
performed as previously described (Zink et al., 1999) and based on histological 
sections and semi-quantitative analysis of perivascular macrophage cuffs; 
sections containing more than 30 cuffs were scored 3, those containing 10-30 
cuffs were scored 2, and those with less than 10 cuffs were scored 1.  The 
recorded score is the average of 6 sections for each animal.  RNA from basal 
ganglia was shipped on dry ice overnight.  Viral load in basal ganglia (SIV RNA 
copy equivalent / μg brain RNA) was analyzed by RT-PCR as previously 
described (Witwer et al., 2009).  A summary of animals analyzed is provided in 
table 1.  Viral load in basal ganglia (SIV RNA copy equivalent / μg brain RNA) 
was analyzed by RT-PCR as previously described.   
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Table 1.  Pigtail macaques analyzed in this study.  (A)  Days post SIV 
infection (B) Number of animals analyzed at each time point (C) Presence (Yes) 
or absence (No) of CNS lesions as determined by perivascular cuffs of 
macrophages as previously described (Zink et al., 1999) (D) Range of basal 
ganglia viral load in animals (SIV RNA copy equivalent / μg brain RNA) detected 
by RT-PCR as previously described (Witwer et al., 2009).  At day 56 post SIV 
infection, viral load data represents 3 of the 6 animals; day 84 post SIV infection, 
viral load data is from 1 animal with no CNS lesion and 2 animals presenting 
CNS lesions.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
day PI
A
      NB      CNS lesionsC    Range of viral loadD     
uninfected   6   No   0   
4   6   No   N/A   
7   3   No   N/A   
10   3   No   2072 - 92130       
14   1   No   N/A   
14   2   Yes   N/A   
21   2   No   N/A   
21   1   Y es   N/A   
42   4   No   49 - 38600     
42   5   Yes   202067 - 26876667       
56   6   Yes   8658333 - 15900000       
84   4 
5 
  No   70   
84   Yes   91 - 3290792   
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Plasmid DNA maxi-prep 
LB broth + Ampicillin (Amp)  (Acros Organics) 20g LB/ L dH2O, autoclaved and 
stored at room temperature.  Ampicillin (Fisher Scientific) at 15 mg/ 250 ml broth 
added prior to use.   
Bacterial glycerol stocks 500 μl transformed bacteria culture and 500 μl 
autoclaved glycerol were stored at -80 °C. 
250 ml of overnight culture was centrifuged at 15,000 xg for 20 minutes at 
room temperature in the Beckman Coulter Avanti J-E superspeed centrifuge.   
The supernatant was removed and 10 ml of cell suspension buffer (PowerPrep 
HP Plasmid Purification Kit, Origene) were added to the pellet.  Following 
resuspension of the pellet, 10 ml of cell lysis buffer (PowerPrep HP Plasmid 
Purification Kit, Origene) were added, mixed by inversion, and incubated at room 
temperature for 5 minutes.  10 ml of neutralization buffer (PowerPrep HP Plasmid 
Purification Kit, Origene) were added to the lysis buffer to stop the reaction and 
mixed well. The lysates were centrifuged 15,000 xg for 10 minutes at room 
temperature to pellet the cell debris.  The lysate was removed and pipetted onto 
cheese cloth covering the maxi-prep purification column (PowerPrep Plasmid 
Purification Kit, Origene), and column was washed with 60 ml of wash buffer 
(PowerPrep HP Plasmid Purification Kit, Origene), the flow through is discarded.  
When the wash buffer had completely exited the column, the column was placed 
on a 15 ml centrifuge tube, and 15 ml of elution buffer (PowerPrep Plasmid HP 
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Purification Kit, Origene) was added to the column.   10.5 ml of isopropanol was 
added, and incubated at -20 ºC overnight minutes to precipitate the DNA.   The 
pellet was resuspended in 500 μl of nuclease free water at 37 ºC for 20 minutes. 
Cell culture 
Buffers and reagents  
Dulbecco’s Modified Eagle’s Medium (DMEM) (Cellgro, Corning): 4.5 g/L glucose 
and 4 mM L-glutamine without sodium pyruvate.  Penicillin and Streptomycin 
(100 U/ml) and FBS (10%) added.  Store at 4 °C. 
Roswell Park Memorial Institute (RPMI) 1640 Medium (Life Technologies, 
Invitrogen) purchased without L-gluatmine:  Supplemented with Penicillin and 
Streptomycin (100 U/ml), L-glutamine (100 U/ml), and FBS (10%).  Store at 4 °C. 
Fetal Bovine Serum (FBS) Certified (GIBCO, Invitrogen), heat inactivated for 60 
minute at 56 °C; 50 ml aliquots stored at -20 °C 
Complete media:  For cell culture, cells grown in appropriate media and 
supplements listed above with 10% FBS.   
Human Embryonic Kidney 293T cells culture 
Human embryonic kidney 293 cells containing the SV40 large T cell 
antigen (HEK 293T) were grown in complete medium DMEM (10 % FBS and 
Penicillin and Streptomycin).  Cells were maintained in 10 cm tissue culture 
 
57 
 
dishes and grown to 75% confluence.  To passage cells, media was removed and 
cells were wash one time with 1x PBS.  1 ml 0.25 % Trypsin-EDTA with phenol 
red (Invitrogen, Life Technologies) was added to cells for 5 minutes; after which 5 
ml of 1x PBS was used to resuspend cells.  Cells were pelleted at 750 xg for 5 
minutes and the pellet was resuspended in 5 ml of complete medium DMEM and 
plated in 10 cm tissue culture dishes (Costar, Corning) at appropriate densities 
for transfections or cell passage.  Cells were grown at 37 °C in 5% CO2.   
Twenty-four hours prior to calcium phosphate (CaPO4) transfection, cells 
were plated at 0.5-1.0 x 106 cells per well of a 6 well tissue culture plate (Costar, 
Corning).  Cells were 60-70% confluent at time of transfection. 
Calcium phosphate transfection 
Transfection reagents were prepared as follows: 2 M CaCl2 to a final 
concentration of 0.12 mM, appropriate DNA concentrations,  2x HEPES buffered 
saline (HBS) (50 mM HEPES, pH 7.05, 10 mM KCl, 12 mM dextrose, 280 mM 
NaCl,1.5 mM Na2PO4), and nuclease free water. One ml of transfection reagent 
was prepared per well of a 6 well plate. For 1ml transfection reagent; DNA, 
CaCl2, and water were mixed first, then HBS was added drop-wise to precipitate 
DNA.  Transfection mixture was allowed to sit for ~5 minutes; then using a 1ml 
pipet, air was bubbled through the transfection mixture, and pipetted drop-wise 
on 60-70% confluent monolayer of HEK 293T in a 6 well tissue culture plate.  
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Transfection efficiency was estimated with GFP reporter as a control, GFP was 
visualized by fluorescence microscopy.   
Packaging of HIV and lentiviral expression constructs  
HEK 293T cells were transfected with 15 μg of HIV-1 DNA:  pNL4.3-
Nef(+)-HSA , Bal-HIV wt, or NL4.3-HIV wt (National Institutes of Health AIDS 
Research and Reference Reagent Program) and 3 μg of RSV-Rev.  For some 
experiments, pNL4.3(+)-HSA was pseudotyped by cotransfecting 3 μg of VSV-G.  
Viral titers were determined by p24 ELISA (Perkin Elmer).  Approximately 1 x 106 
pg/ml p24 of infectious virus were added to each well for infection.   
p21 expressing lentiviruses were generated by cotransfecting HEK 293T 
cells with 15 μg of flap-Ub promoter-GFP-WRE  (FUGW) -empty or FUGW-p21-
Flag, 3 μg Tat, 3 μg of RSV-Rev and 3 μg pCMVΔR8.9  encoding Gag-Pol.   
Tissue-resident macrophage cultures 
Tonsil explants were obtained from National Disease Research 
Interchange (NDRI) or discarded tissues from otolaryngology surgeries 
performed at Boston Medical Center (BMC).   Tissue from NDRI was processed 
upon receipt of overnight shipment on ice.   Deidentified and discarded tonsil 
tissues from BMC were processed within hours after surgery.  The use of human 
tonsils was reviewed by the Boston University Institutional Review Board and 
determined to be exempt.  Clean forceps and scissors were sterilized in absolute 
 
59 
 
ethanol, and allowed to dry.  Tonsil tissue was dissected into 1-2 mm2 pieces with 
scissors and forceps in serum-free DMEM with Penicillin and Streptomycin (P/S), 
in a sterile 10 cm tissue culture dish. Several tissue pieces were transferred at a 
time to a large tissue grinder (Kendall) with 5 ml serum-free DMEM.  The tissue 
was homogenized with ~10 twists of the pestle.  The homogenate was passed 
through a 70 μm nylon filter (BD Falcon) resulting in a single cell suspension.  
The final volume of the cell suspension was adjusted to 50 ml.  Twenty-five ml of 
cell suspension was carefully layered onto 12 ml room temperature Histopaque 
1077 (Sigma Aldrich) in a 50 ml conical tube.  The tube was centrifuged at 700 xg 
for 20 minutes with no brake.  The top layer was discarded, and the monolayer of 
mononuclear cells at the interface of DMEM and Histopaque was collected.  
Cells were washed 3 times in 1x PBS, and cultured in serum-free DMEM with 
P/S at 1.0-2.0 x 107 cells per ml (Fig. 10) .   
Prior to use, cells were matured in culture. Initially, cells were serum 
starved for 2 hours, after which the majority of cells attached to the plate.  Cells 
were washed twice with 1x PBS, and provided fresh complete medium DMEM 
and anti-mycotic with amphotericin B (0.50 μg/ml) (Fungizone, Invitrogen). Cells 
were washed twice in 1x PBS the following day and fresh complete medium 
DMEM and anti-mycotic.  Cells were washed every 2 days thereafter, and remain 
cultured in anti-mycotic for 3-4 days. Following 7 days in culture, cells were 
strongly adherent and included elongated, spindle shaped cells as well as more 
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rounded cells.  Cells were maintained at 37°C in 5% CO2 and were dislodged 
using a cell lifter. 
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A. B. C.
D.E.F.
 
 
Figure 10.  Isolation of tonsil derived tissue-resident macrophages.  (A)  
Tissue-resident macrophages were isolated from discarded tonsil tissue.  (B)  
Tonsil tissue was into 1-2 mm2 pieces with scissors and forceps in a sterile 10 cm 
tissue culture dish and (C) homogenized with ~10 twists of the pestle.  (D)  
Homogenate was passed through a 70μm filter, then (E) layered onto a 
Histopaque.  (F)  Cells from the monolayer were seeded on a 6 well tissue 
culture plate. 
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Primary T cell cultures from peripheral human blood 
Leukopaks were purchased and shipped overnight from New York 
Biologics, Inc.  Leukopaks contained approximately 200 ml of whole peripheral 
blood.  A single leukopak was divided equally into four 50 ml conical tubes and 1x 
PBS was added to increase the total volume to 40 ml.  Blood was centrifuged for 
15 minutes at 1,200 xg at room temperature with no brake.  The top plasma layer 
was discarded; the volume was adjusted with 1X PBS to 25 ml per tube, and 
overlayed onto 15 ml Histopaque in 50 ml conical tubes. The tube was 
centrifuged at 700 xg for 20 minutes with no brake.  The top layer was discarded, 
and the monolayer of mononuclear cells at the interface was collected.   
Peripheral blood mononuclear cells (PBMC) were washed 3 times in 1xPBS, and 
cultured in complete medium RPMI (with 10 % FBS, P/S, and L-glutamine) in 1-2 
T-75 flasks (30 ml / T75 flask), depending on cell density.  Cells were maintained 
at 37°C in 5% CO2.   
Following overnight culture, PBMCs were resuspended in 1x PBS plus 2 
% FBS at a concentration of 1.5 x 107 cells per ml and kept on ice.  25 μl of CD4+ 
magnetic beads (Dynal, Invitrogen) were prepared per 1 ml of PBMC cell 
suspension.   
Beads were washed prior to adding cells.  Beads were placed on magnet 
(Dynal, Invitrogen) for 1 minute; magnet was tilted to remove liquid without 
disturbing beads.  Beads were removed from the magnet, 1x PBS plus 2% FBS 
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was added 1 ml/1 ml of cell suspension, and replaced on the magnet for 1 
minute.  Beads were washed three times before resuspending in 1x PBS plus 2% 
FBS at original bead volume.   
Cell suspension (1.5 x 107 cells per ml) was added to each 15 ml conical 
tube with washed magnetic beads and incubated at 4 °C for 20 minutes on a 
nutator.  Following incubation, beads were placed on magnet for 3 minutes, and 
the CD4 negative supernatant was discarded.  Beads were washed three times, 
as before, with 1x PBS plus 2% FBS.  Following the final wash, cells and beads 
were resuspended at 1.5 x 107 cells per ml in RPMI, 1 %FBS. 
Detach-a-bead reagent (Dynal, Invitrogen) was added at 10 μl/1 ml of cell 
suspension and incubated at room temperature for 60 minutes on a nutator.   
Following incubation, tubes were placed on magnet for 3 minutes, and CD4 
positive cells were collected in the flow through.   Beads were washed three 
times, as before, with 1 ml of RPMI, 1 %FBS /1 ml of cell suspension.  CD4+ T 
cells were pelleted at 750 xg for 5 minutes, resuspended in complete medium 
RPMI for culture in 1-2 T75 flasks (30 ml / T 75 flask), depending on cell density.  
Cells were maintained at 37°C in 5% CO2.   
 PBMC from HIV+ elite controllers and seronegative controls were isolated 
at the Broad Research Institute in accordance with federal guidelines and 
institutional policies and archived at -80°C.  CD4+ T cells were stimulated with IL2 
and CD3/CD8 for 5 days.  Following stimulation, 5M CD4+T infected with NL4.3 
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for 7 days as previously described.  Cells fixed in 1% formaldehyde to cross-link 
proteins for chromatin immunoprecipiation.  Cells were pelleted and excess liquid 
was removed.  Cell pellets were snap frozen and delivered on dry ice. 
CD4+ T cell activation 
CD4+ T cells were activated with 10 ng/ml Phytohaemagglutinin (PHA) and 
2 μg/ml Phorbol myristate acetate (PMA) overnight.  Following activation, cells 
were washed once with 1xPBS and resuspended in complete medium RPMI in 1-
2 T-75 flasks (30 ml / T75 flask), depending on cell density.  Cells recovered at 
37°C in 5% CO2 for at least 4 hours prior to use. 
HIV-1 infections of macrophage cultures 
Approximately 1 x 106 pg/ml p24 of infectious virus were added to cells in 
a 6 well tissue culture plate for HIV infection. 24 hours post infection, cells were 
washed twice with 1x PBS to remove initial infectious virus; fresh complete 
medium DMEM was added, and cells were treated with MSP or siRNA (Fig. 11). 
HIV-1 infections of T cell cultures 
Approximately 1 x 106 pg/ml p24 of infectious virus were added to cells for 
HIV-1 spinoculation (O'Doherty et al., 2000).  To spinoculate, T cells were 
centrifuged with virus and 2 μg/ml polybrene at 650 xg for 90 minutes.  Following 
spin, cells were resuspended in the virus and incubated at 37°C in 5 % CO2 for 
24 hours.  24 hours post infection, cells were washed twice with 1x PBS to 
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thoroughly remove initial infectious virus; fresh complete medium RPMI was 
added (Fig. 11).   
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Figure 11.  Time line of in vitro HIV infections.    (A)  Tissue-resident 
macrophages were infected with HIV for 18 hours, cells were wash 2 times with 
1x PBS and treated with MSP or siRNA.  Treatments remained on cells for 48 
hours, after which samples were collected.  (B)  Human primary CD4+ T cells 
were infected with activated with PMA and PHA for 18 hours.   Cells were 
washed 2 times with 1x PBS and allowed to rest for at least 4 hours, after which 
cells were spinoculated with FUGW empty or p21-flag expressing lenitvirus for 18 
hours, then spinoculated to infect with HIV.  Samples were collected 24 hours 
post HIV infection.   
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Overexpression of p21  
Approximately 1 ml filtered FUGW-p21-flag were added to appropriate 
cells for spinoculation.  T cells were centrifuged with virus and 2 μg/ml polybrene 
at 134 xg for 90 minutes.  Following spin, cells were resuspended in the virus 
and incubated at 37°C in 5% CO2 for 24 hours.  Twenty-four hours post infection, 
cells were washed twice with 1x PBS to remove initial infectious virus; fresh 
complete medium RPMI was added (Fig. 11). 
Cytokines and macrophage stimulating protein (MSP)  
MSP (R&D Systems) was used at 100 ng/ml as either a pretreatment 
overnight prior to cytokine stimulation, or 24 hours following infection. IFNɣ (R&D 
Systems), at 1,000 U/ml, and LPS (Sigma-Aldrich) at 10 μg/ml, were used to 
stimulate cells in vitro for 4 hours (Fig. 11).  
siRNA depletion of RON  
RON (MST1R) OnTarget plus SMARTpool siRNA (25 nM; Dharmacon) 
and control nontargeting SMARTpool siRNA (25 nM; Dharmacon) were 
transfected into tissue-resident macrophages 24 hours post infection using 
TransIT-TKO transfection reagent (Mirus). Transfection reagents were prepared 
in serum-free DMEM and 1/100 volume of TransIT-TKO reagent and allowed to 
equilibrate at room temperature for 20 minutes before adding siRON or 
siNontargeting pool siRNA for an additional 20 minutes at room temperature. For 
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transfection of siRNA in 6 well plates, approximately 1 X 106 tonsil derived 
macrophages were washed with PBS twice to remove initial infectious virus, 
replenished with 1.25 ml complete medium DMEM and 240 μl siRNA transfection 
mixture was added dropwise to cells. siRNA transfections of 1 X 107 cells in 10 
cm plates were performed with 9 ml of DMEM-transfection mixture. Transfection 
reagents were incubated with cells for 48 hours and cells were collected for RNA 
and protein (Fig. 11).  Knockdowns were validated by western blot or mRNA for 
RON expression. 
Polymerase Chain Reaction 
PCR stock solutions and buffers 
10 mM dNTP mix (10 mM each dATP, dTTP, dGTP, and dCTP, Fisher Scientific) 
10x PCR reaction buffer (100 mM Tris-HCl, pH 9.0 [at 25°C/77°F]; 500 mM KCl; 
15 mM MgCl2, Fisher Scientific) 
10 μM primer stock solutions for PCR, 5 μM stock solutions for real time PCR in 
nuclease free water 
5x Tris/borate/EDTA buffer (TBE) (446 mM Tris base, 445 mM Boric Acid, and 10 
mM EDTA in dH20) 
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Gel electrophoresis reagents 
10 % Ammonium persulfate (APS) 10 % APS (Fisher scientific) in dH20.  Stocks 
were stored at -20 °C. 
1 % Agarose  1 % electrophoresis grade agarose in 1x TBE  
8% Non-denaturing acrylamide gel  For one vertical electrophoresis set up make 
30 ml of gel.  6 ml 5x TBE, 8 ml 30 % Bis-Acrylamide 29:1, 22.5 μl N,N,N',N'-
Tetramethylethylenediamine (TEMED) in dH20. 
6x DNA loading dye  0.25 % Bromophenol blue, 0.25 % Xylene cyanol/FF, 30 % 
glycerol in dH20 
General PCR procedure 
A PCR reaction containing:  2.5 μl template, 2.5 μl10x reaction buffer, 1 
μM of each primer (table 2), 200 μM of dNTP mix (stock containing 10 mM of 
dATP, dTTP, dCTP, and dGTP), and 1.25 U Taq polymerase (Fisher Scientific) to 
a 25 μl volume in nuclease free water was mixed in 200 μl PCR tube (Fisher 
Scientific).  Reactions were run on a thermocylcer for 95 °C for 3 minutes, 20-30 
cycles of denaturation: 95 °C for 1 minute, annealing: 56 °C (unless otherwise 
noted) for 1 minute, and extension: 72 °C for 1 minute, followed by a final 
extension at 72 °C for 10 minutes.  Conditions were optimized for each primer 
set.  PCR products were stored at -20 °C for long term storage or at 4 °C for use 
within the week. 
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RNA extraction and real-time reverse transcriptase (RT) PCR 
RNA extraction 
RNA from basal ganglia was extracted as previously described, shipped 
overnight on dry ice, and stored at -80 °C. Representative animals from 
uninfected (3 of 6 animals), day 42 post SIV infection (4 of 9 animals) and day 84 
post SIV infection (6 of 9 animals) were analyzed.   
RNA from in vitro cultures was extracted using Trizol Reagent (Invitrogen).  
Following removal of spent media from cultured cells, 1 ml of 1x PBS was added 
to each well and a sterile cell lifter (Fisher Scientific) was used to release 
adherent cells.  Cells were collected in 1.5 ml microcentrifuge tubes.  Each well 
was washed with 500 μl 1x PBS to ensure residual cells were collected, and cells 
were spun at 16,000 xg for 5 minutes to pellet the cells, the supernatant was 
removed, and the pellet was resuspended in 1 ml of Trizol reagent.  The Trizol 
was pipetted several times to lyse the cells.  Cell lysates in Trizol were stored in -
20 °C until further processing.   
 Lysates in Trizol were extracted with 200 μl of chloroform / 1 ml Trizol.  
Samples were shaken vigorously for 15 seconds, incubated at room temperature 
for 3 minutes, and then centrifuged at 12,000 xg at 4 °C for 15 minutes.  
Following phase separation, the aqueous phase was transferred to a new 
microcentrifuge tube.  500 μl of isopropanol was added to each tube 
(approximately 60% of initial Trizol volume), and the sample was mixed gently by 
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inversion.  The sample was incubated overnight at -20 °C.  The isopropanol 
mixture was centrifuged at 12,000 xg at 4 °C for 10 minutes.  The isopropanol 
was removed, and the RNA pellet was washed 1 x with 75% ethanol prepared 
with RNase free water.  The RNA pellet was centrifuged at 7,500 xg at 4 °C for 5 
minutes.  Ethanol was carefully removed, the tube was inverted, and the pellet 
was allowed to air dry for 1 hour to overnight.  The RNA pellet was resuspended 
in 30 μl RNase free water and stored at -80 °C. 
cDNA preparation 
RNA from brain and in vitro cultures was reversed transcribed using 
SuperScript II Reverse Transcriptase (Invitrogen).  Approximately 1 μg of RNA 
was used for each reverse transcription reaction.  The cDNA “reaction 1” 
contained 1 μg of RNA, 100 ng random primers (Promega), 833 nM dNTP, in 
RNase free water to a final volume of 12 μl in a 200 μl PCR reaction tube (Fisher 
Scientific).  cDNA “reaction 1” was incubated for 5 minutes at 65 °C in a 
thermocylcer.  “Reaction 2” mixture was added to “reaction 1” as a master mix, 
for a final reaction containing 4 μl 5x 1st strand buffer (250 mM Tris-HCl, pH 8.3 at 
room temperature; 375 mM KCl; 15 mM MgCl, Invitrogen), 2 μl 0.1M DTT 
(Invitrogen), 4 U RNasin (Promega), and 100 U of Superscript reverse 
transcriptase II (Invitrogen) to a final reaction volume of 20 μl.  The reaction was 
mixed by pipetting up and down gently, and run on a thermocylcer at 45 °C for 50 
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minutes followed by 70 °C for 15 minutes.  Afterwards, 80 μl of RNase free water 
was added to the 20 μl reaction volume for a total 100 μl of cDNA.   
Real-time reverse transcriptase (RT) PCR 
Real time RT-PCR was performed using Go Taq Master Mix (Promega).  5 
μl of cDNA was used as a template in a reaction containing 7.5 μl Promega Go 
Taq Master Mix (containing Taq polymerase in a buffer containing 7.5mM MgCl2), 
0.42 μM forward and reverse primers (Table 2, 5 μM stock primers) or 1.5 μl β-
actin primer (Qiagen) in a total reaction volume of 15 μl.  Samples without 
template or reverse transcriptase were used as controls.  Triplicates were 
performed for each primer pair and sample.  Reactions were performed in 96 well 
optical reaction plates (Applied Biosystems).  Plates were centrifuged lightly at 
100 xg for ~5 minutes to ensure reaction volume was settled at the bottom of the 
well.  Samples were processed using ABI Prism 7000 Sequence Determination 
Software (Applied Biosystems): 15 minutes at 94 °C, followed by 40-50 cycles of 
15 seconds at 94 °C, 30 seconds at 56 °C, and 32 seconds at 72°C. Conditions 
were optimized for each primer set.  Data was collected during the elongation 
step.  Triplicate samples were normalized to β-actin individually to account for 
total error, and an average and standard deviation of the triplicates were 
presented.  
Relative quantification was used to analyze gene expression of targets 
without plasmid DNA required to generate a standard curve.  Samples were 
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processed using the relative quantification program (Applied Biosystems), and 
analyzed using the relative study program (Applied Biosystems), with β-actin set 
as the endogenous control.  The cycle threshold (CT) was set in the middle of the 
linear range of the amplification curves for each gene target.  Relative expression 
was calculated using the delta-delta CT        (2-ΔΔct) method (Livak and 
Schmittgen, 2001), using β-actin as an internal control and uninfected conditions 
as the calibrator: 
2-ΔΔct= 2 - (CT unknown target – CT unknown β –actin) – (CT calibrator target – CT calibrator β –actin) 
Wild-type RON, wild-type p21, and β-actin plasmids were used to 
generate standard curves.  Stock plasmid DNA was serial diluted to obtain 1 ng, 
10 pg, 100 fg, and 1 fg standards which were added to the plate in triplicate.  
Samples were processed using the absolute quantification program (Applied 
Biosystems).  Quantities were extrapolated from the standard curve, and values 
were calculated by normalization to the β-actin control.   
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Table 2.  RT-PCR primers 
Primer  Forward/Sense   Reverse/Anti-Sense   
Arginase I cagaagaatggaagagtca
g 
cagatatgcagggagtcacc 
HIV-1 initiated (+1-+40) gggtctctctggttaga agagctcccaggctca 
HIV-1 elongated (+5396-
+5531) 
gcttcttcctgccataggag gactagagccctggaagca 
Interleukin 12 p40 gcgtgcaagctcaggatcg ttagctccctggctctgcg 
Tumor Necrosis Factor α aactagtggtgccagccgat cttcacagagcaatgactcc 
RON tagcagtgcaacccctcttt gtaaagccagcagctccatc 
Interleukin 6 cagaaagccagagtccttca
gagag 
ctaggtttgccgactagatctc 
Interleukin-1 Receptor 
Antagonist 
cccttctgggaaaagaccct
gcaag 
gaacttcgtgactataagggg
ctc 
Scavenger Receptor A attgccctttacctcctcgt ccatgttgctcatgtgttcc 
 
Inducible Nitric Oxide 
Synthetase 
aatggcaacatcaggtcgg
ccatcact 
gctgtgtgtcacagaagtctcg
aactc 
p21 Subcloning ctggatccacgcgtatcg gaggcactggggagg 
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Table 3.   ChIP primers 
Primer Forward Reverse 
HIV-1 (+30 to +134) ctgggagctctctggtaacta ttaccagagtcacacaacagac 
HIV-1 (-42-+72) gagccctcagatcctggata aggcttaagcagtgggttcc 
HIV-1 (+155 to +186) ccgagagctgcatccggagt actgctagagattttccacact 
HIV-1 (+2415-+2690) gtaacagtactggatgtgggtgatg ctgccctatttctaagtcagatcc 
 
 
Real-time PCR for Chromatin immunoprecipitation  
Input DNAs for each sample were used to generate a standard curve to 
calculate binding of each immunopreciptiated protein.  Input DNA was serial 
diluted to obtain 5 %, 2.5 %, 1.25 %, and 0.6 % dilutions which were added in 
triplicate.  Samples were processed using the absolute quantification program 
(Applied Biosystems).  The cycle threshold (CT) was set in the middle of the 
linear range of the amplification curves.  Quantities extrapolated from the 
standard curve, and values were calculated by normalization to the β-actin 
control.  Each sample was analyzed using its own input DNA standard curve.  
Triplicate samples were normalized individually to account for total error, and an 
average and standard deviation of the triplicates was presented. (Table 3)  
 
 
 
76 
 
Chromatin immunoprecipitation 
Buffers 
Sonication Buffer:  10 mM Tris-HCl pH8.0, 1 mM EDTA, 0.5 mM EGTA, 1 % SDS, 
1 μg/ml Aprotinin, 1 μg/ml  Pepstatin A, and 0.5 mM PMSF. 
TE Buffer:  10 mM Tris-HCl and 1 mM EDTA. 
Low Salt Wash Buffer:  0.1% SDS, 1% Triton X, 2 mM EDTA, 20 mM Tris-HCl pH 
8.0, and 150 mM NaCl. 
High Salt Wash Buffer:  0.1% SDS, 1% Triton X, 2 mM EDTA, 20 mM Tris-HCl 
pH8.0, and 500 mM NaCl.   
Lithium Wash Buffer:  0.2 5mM LiCl, 1% NP-40, 1% Sodium Deoxycholate 
(C24H39O4Na), 1 mM EDTA, and 10 mM Tris-HCl pH 8.0. 
Elution Buffer:  1 % SDS and 0.1 M NaHCO3. 
3 M NaOAc  3 M Sodium Acetate in dH20.  Stored at room temperature. 
Chromatin immunoprecipitation  
Formaldehyde (37 wt. % in H2O, contains 10-15% Methanol as stabilizer) 
was added to cells (without removing the media) to a 1% solution, and incubated 
at room temperature for 10 minutes.  Glycine (240 nm stock solution) was added 
at a final concentration of 240 nM to quench the cross-linking.  Cells were 
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centrifuged at 700 xg for 10 minutes and washed 2x in cold 1x PBS.  Following 
washes, cell pellets were snap frozen in liquid nitrogen and stored at -80 °C.   
Cell pellets were resuspended in 1 ml of freshly prepared sonication 
buffer, and sonicated in an ice bath using a Sonifier 450 (Branson) and cup horn 
for 30 cycles:  20 seconds on and 10 seconds off, with an output control of 5.   
Five μl of sonicated DNA was treated with 1 μl of RNase A and 2 μl 
proteinase K at 55 °C overnight.  Sonicated DNA was run on 1% agarose to 
confirm DNA smears of approximately 200 bp.   
Sonicated DNA was precleared with sepharose A beads (GE Healthcare).  
40 μl sepharose A beads were added to DNA and mixed on a nutator at 4 °C for 
30 minutes.  DNA was centrifuged at 200 xg and pre-cleared DNA was used 
immediately or stored at -20°C. 
Following pre-clear, 25-100 μl of sonicated DNA was alliquoted to one 1.5 
microcentrifuge tube per immunoprecipitation.  1 μg of each antibody (Table 5) 
was added to chromatin sample and incubated for 2 hours at 4 °C on a nutator.   
The following 1 ml washes were performed:  2 washes with low salt buffer, 
2 washes with high salt buffer, 2 washes with lithium chloride buffer, and 2 
washes with TE buffer.  Each wash consisted of a 5 minute incubation at 4 °C on 
a nutator followed by a 5 minute centrifugation at 200 xg at 4 °C. 
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Immunopreciptated DNA was eluted with 250 μl elution buffer for 15 
minutes at room temperature on a nutator.  DNA was centrifuged at 200 xg for 5 
minutes, the elution was removed and placed in a new 1.5 ml microcentrifuge 
tube.  Beads were eluted a second time with 250 μl elution buffer for 15 minutes 
at room temperature on a nutator, centrifuged at 200 xg for 5 minutes, and the 
elution was saved.  During the elution step 10% of each sample of pre-cleared 
DNA was used for the input control.  
Twenty μl of 5M NaCl was added to each elutant and incubated at 65 °C 4 
hours to overnight to reverse the cross links.   
Ten μl of 0.5M EDTA, 20 μl 1M Tris-HCl, and 36 μg proteinase K (2 μl of 
10 mg/ml stock) were added and incubated at 45 °C for 1 hour. 
Five hundred μl of phenol:cholorform:isoamyl were added to each sample, 
shaken vigorously and centrifuged at 16,000 xg for 5 minutes.  The aqueous 
phase was removed to a new 1.5 ml microcentrifuge tube and a second 
phenol:cholorform:isoamyl extraction was performed followed by a single 
chloroform extraction.   
DNA was precipitated with 20 μg linear polyacrylamide, 50 μl 3M NaOAc, 
and 1 ml 100% absolute ethanol.  The sample was incubated overnight -20 °C, 
additionally, the precipitation step can be stored at -20 °C.    The precipitation 
reaction was centrifuged at 16,000 xg at 4 °C for 30 minutes.  The DNA pellet 
was carefully washed 1 x with 75 % ethanol (in with nuclease free water).  The 
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DNA pellet was centrifuged at 16,000 xg at 4 °C for 10 minutes.  The ethanol was 
carefully removed, the tube was inverted, and the pellet was allowed to air dry for 
1 hour to overnight.  The pellet was resuspended in 30 μl of nuclease free water 
and stored at -80 °C. 
Generation of p21 overexpression construct 
Wild-type flag p21 (plasmid 16240, Addgene) plasmid contained a single 
BamHI restriction enzyme site at the position 629 of the p21 insert. (Fig. 12)  
Using a PCR strategy (Table 4), an additional BamHI site was added to the 
beginning of the insert (Fig. 12), prior to the flag sequence through a mismatch of 
two base pairs (Fig. 19).   
Table 4.  P21 Subcloning primers 
Primer Position Sequence Annealing 
temp 
P21 Forward 2 1-18 ctggatccacgcgtatcg 54 °C 
P21 Reverse 1 650-670 gaggcactggggagg 54 °C 
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Figure 12.  FUGW and FUGW-p21-flag maps.  (A) FUGW lenitviral vector is 
9941 bp, and contains a single BamHI restriction enzyme site at +3848.  (B)  
Wild-type p21-flag is 809 bp with a flag sequence prior to the p21 insert at +89.  
The wild-type plasmid contains a single BamHI restriction enzyme site at +629 
and a single NdeI site at +132.  (C)  The p21 insert, with a second BamHI site, is 
ligated into the single BamHI site of the FUGW empty vector to create the 
pFUGW p21-flag plasmid. (D)  Two NdeI sites (at +486 and +3980) were used to 
verify correct orientation of the p21 insert.   
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Wild-type flag p21 plasmid DNA was serial diluted to 10 ng, 1 ng, and 100 
pg.  2.5 μl of each dilution was used as the template in a PCR reaction with an 
annealing temperature of 54 °C and 30 cycles.  PCR products were run on 1 % 
agarose gel, and a 670 bp band confirmed a successful reaction.  Both 10 ng 
and 1 ng templates yielded sufficient product. 
One μg of DNA , p21 cDNA with two BamHI sites or FUGW empty vector 
with a single BamHI site,  was cut with 20 U BamHI (New England Biolabs (NEB)  
in 2 μl New England Biolabs (NEB) buffer 3 (stock solution:  100 mM NaCl, 50 
mM Tris-HCl, 10 mM MgCl2, 1 mM DTT) with 5 μg bovine serum albumin (BSA) 
in a reaction volume of 20 μl.  FUGW restriction enzyme reaction contained 1 U 
calf intestinal phosphatase (CIP, New England Biolabs).  Reaction was incubated 
in a 37 ºC water bath for 1 hour.  Reaction products were run on 1 % agarose 
gel, and the 646 bp product was cut out and extracted with a gel extraction kit 
(PowerPrep Express Gel Extraction kit, Origene).   
Excised gel containing DNA was placed in 1.5 ml microcentrifuge tube, 
with a maximum of 400 mg per tube.  Gel was weighed, 30 μl of gel solubilization 
buffer kit (PowerPrep Express Gel Extraction kit, Origene) was added for every 
10 mg of gel, and incubated at 50 ºC for 15 minutes (mixing every 3 minutes).  
Solubilized gel was loaded onto the cartridge, containing a silica membrane, in a 
provided 1.5 ml microcentrifuge tube and centrifuged at 12,000 xg for 1 minute.  
The flow through was discarded.  700 μl of wash buffer (containing ethanol) 
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(PowerPrep Express Gel Extraction kit, Origene) was added to the cartridge and 
incubated at room temperature for 5 minutes.  The cartridge was centrifuged at 
12,000 xg for 1 minute and the flow through was discarded.  The cartridge was 
then centrifuged at 12,000 xg for 1 minute without additional wash buffer to 
remove residual wash buffer.  The cartridge was placed in the provided recovery 
tube and 50 μl of provided TE buffer, pre-warmed to 65-70 ºC was added to the 
center of the cartridge and incubated for 1 minute at room temperature.  The 
cartridge was centrifuged at 12,000 xg for 2 minutes.  The flow through contained 
the extracted DNA.   
Five μl of reaction products were run on 1 % agarose gel to confirm 
successful extraction, and estimate concentration of extracted DNA, using 
concentration of 100 bp ladder (exactGene, Fisher Scientific) size marker as a 
reference. 
The p21 DNA was ligated into the FUGW plasmid in a ligation reaction 
containing approximately 100 ng of the BamHI cut FUGW empty vector and 32 
ng insert. 
FUGW and p21 were included in a ligation reaction containing 3 μl 10X 
ligase buffer (300 mMTris-HCl (pH 7.8), 100 mM MgCl2, 100 mM DTT and 10 mM 
ATP), 3U T4 DNA ligase (3 U/ μl), in nuclease free water in a 30 μl reaction 
volume in a 200 μl PCR tube.  Ligation reaction was incubated at 16 ºC overnight 
in a thermocycler.  Ligation products were stored at -20 ºC. 
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E. coli transformation 
Ligation reaction product was used to transform E. coli bacteria (One Shot 
TOP 10 chemically competent, Invitrogen).  Bacteria were thawed on ice 10 
minutes (1 vial/ transformation plus one control transformation with pUC19 
bacteria, provided).  Five μl ligation product and 1 μl pUC19 control DNA (10 pg) 
were added to bacteria and incubated on ice for 30 minutes.  Bacteria were heat 
shocked for 30 seconds at 42 ºC, and immediately placed on ice for 2 minutes.  
Two hundred fifty μl pre-warmed Luria Bertani (LB) broth without antibiotics were 
added to each vial of bacteria, and the bacteria were incubated at 37 ºC on a 
shaker for 1 hour.  Following incubation, 200 μl and 50 μl of transformed bacteria 
were spread on 2 pre-warmed LB agar plates with ampicillin (60 μg/ml) for each 
transformation.  Plates were incubated at 37 ºC overnight and colonies were 
harvested the following day.  pUC19 control growth was monitored to ensure 
transformation efficacy. 
Each bacteria clone was removed from the agar and placed in 5 ml of LB 
with ampicillin (60 μg/ml) overnight in 14 ml polystyrene round bottom tubes 
(Fisher Scientific).  Following overnight culture, 1.5 ml of the mini culture was 
used for a DNA mini-prep to determine if the insert was in the proper 
conformation.  The remaining culture was stored at 4 ºC to prevent overgrowth. 
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DNA mini-prep and Nde1 digest to validate p21 insert orientation  
DNA mini-prep were performed using 1.5 ml of overnight mini culture and 
reagents and protocol for maxi-prep (PowerPrep HP Plasmid Purification Kit, 
Origene).  without purification columns.  Overnight mini culture was centrifuged at 
in 1.5 ml microcentrifuge tube at 16,000 xg for 5 minutes, the supernatant was 
removed and 100 μl of cell suspension buffer were added to the pellet.  Following 
resuspension of the pellet, 200 μl of cell lysis buffer were added, mixed by 
inversion, and incubated at room temperature for 2 minutes.  One hundred and 
fifty μl of neutralization buffer were added to the lysis buffer to stop the reaction 
and mixed well.  The lysates were centrifuged 16,000 xg for 10 minutes to pellet 
the cell debris.  The lysate was removed to a new 1.5 ml microcentrifuge tube 
and 500 μl of phenol:chloroform:isoamyl were added and mixed thoroughly.  The 
phase separation was centrifuged at 16,000 xg for 10 minutes, and the aqueous 
phase was removed to a new 1.5 ml microcentrifuge tube.  1 ml of absolute 
ethanol was added, and incubated at -20 ºC for 30 minutes to precipitate the 
DNA.  The pellet was resuspended in 30 μl of nuclease free water at 37 ºC for 20 
minutes. 
Five μl of DNA was cut with 20U NdeI (New England Biolabs (NEB) ) in 2 
μl 10 X New England Biolabs (NEB) buffer 4 (stock solution:  50mM potassium 
acetate, 20mM Tris-acetate, 10mM magnesium acetate, 1mM DTT) in a reaction 
volume of 20 μl.  FUGW restriction enzyme reaction contained 1U calf intestinal 
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phosphatase (CIP, New England Biolabs).  Reaction was incubated in a 37 ºC 
water bath for 1 hour. 
Five μl of reaction products were run on 0.8% agarose gel to determine if 
the p21 insert was added in the correct orientation (Fig. 12).  A single clone 
contained the properly inserted flag-p21. 
Table 5.   Antibodies 
Antibody Isotype Vendor Clone/ 
cat # 
Application 
FITC CD14 m IgG2a,κ BD Biosciences M5E2 Flow (primary) 
FITC CCR5  BD Biosciences 2D7/CCR5 Flow (primary) 
PE-Cy5CD16 m IgG1,κ BD Biosciences 3G8 Flow (primary) 
PE-Cy5 CD206 m IgG1,κ BD Biosciences 19.2 Flow (primary) 
CXCR4 m IgG2a,κ NIH 12G5 Flow (primary) 
PE-Cy5 CD16 m IgG1,κ BD Biosciences 3G8 Flow (primary) 
PE-Cy5 CD11b m IgG1,κ BD Biosciences ICRF44  Flow (primary) 
PE CD36  m IgM, κ BD Biosciences CB38 Flow (primary) 
PE TREM-2 rat IgG2B R& D Systems 237920 Flow (primary) 
Ron β m IgG1  Santa Cruz  sc80328 Flow (primary) 
FITC m IgG2a CXCR4 BD Biosciences R19-15 Flow (secondary) 
FITC g IgG1 Ron β BD Biosciences sc2078 Flow (secondary) 
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rabbit IgG  Millipore 12-370 ChIP (control) 
Flag  Sigma Aldrich M2 ChIP (control) 
RNA polymerase 
II 
rabbit IgG Santa Cruz N-20 ChIP  
NELFb (COBRA) rabbit IgG Abcam ab48336 ChIP 
PCF11 rabbit IgG D. Gilmour (Wu et al., 
2003) 
ChIP 
acH3 rabbit IgG Millipore 06-599 ChIP 
acH4 rabbit IgG Millipore 06-598 ChIP 
RON β rabbit Santa Cruz C-20 Western (primary) 
p21 mouse Santa Cruz 187 Western (primary) 
β-actin mouse Sigma Aldrich AC-74 Western (primary) 
Flag mouse Sigma Aldrich M2 Western (primary) 
mouse IgG-HRP  Sigma Aldrich M4280 Western 
(secondary) 
rabbit IgG-HRP  Sigma Aldrich A0545 Western 
(secondary) 
 
Western blot  
Buffers and gels 
Whole Cell Lysis Buffer:  10mM Tris-HCl pH 7.4, 150mM NaCl, 1mM EDTA, 2mM 
sodium vandate (Na3VO4), 10 mM sodium fluoride, 10 mM sodium 
pyrophosphate, and 0.1 % NP-40, with protease Inhibitors added fresh prior to 
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each use (cocktail inhibitors set III, Calbiochem) added at a concentration of 1 μl 
inhibitor set/1 ml lysis buffer and 1 mM PMSF.  Cocktail Inhibitor set III contains:  
100 mM AEBSF, hydrochloride (serine proteases), 80 μM aprotinin (broad 
spectrum, serum proteases), 5mM bestatin (aminopeptidase B and leucine 
aminopeptidase), 1.5 mM E-64 (cysteine proteases), 2 mM leupeptin, 
hemisulfate (cysteine proteases and trypsin-like proteases), and 1 mM pepstatin 
A (aspartic proteases). 
5x Tris-Glycine Electrophoresis Buffer:  For 1 L stock solution to be used at 1x 
diluted in dH20 for use.  125 mM Tris base and 1.25 M Glycine.   
Transfer Buffer:  Prepare fresh.  38 mM Glycine, 48 mM Tris base, 0.037 %  
SDS, and 20 % Methanol. 
2x SDS Loading Dye:  100 mM Tris-HCl (ph 6.7), 4 % SDS, 0.2 % bromophenol 
blue, and 20 % glycerol.  Add 200 nM DTT immediately before adding to lysate. 
10% Ammonium persulfate (APS) 10 % APS (Fisher scientific) in dH20.  Stocks 
stored at -20 °C. 
1M Dithiothreitol (DTT)  1 M DTT (Sigma Aldrich) in dH20.  Stocks stored at -20 
°C. 
6 % Resolving SDS-PAGE Gel:  6 % Acrylamide: Bis-Acrylamide 29:1, 375 mM 
Tris-HCl pH 8.8, 0.1 % SDS, 0.1 % Ammonium Persulfate, and 5 mM TEMED 
(N,N,N',N'-Tetramethylethylenediamine).   
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8 % Resolving SDS-PAGE Gel:  8 % Acrylamide: Bis-Acrylamide 29:1, 375 mM 
Tris-HCl pH 8.8, 0.1 % SDS, 0.1 % Ammonium Persulfate, and 4 mM TEMED.   
5 % Stacking SDS-PAGE Gel: 5 % Acrylamide: Bis-Acrylamide 29:1, 130 mM 
Tris-HCl pH 6.8, 0.1 % SDS, 0.1 % Ammonium Persulfate, and 6.5 mM TEMED.   
1x Phosphate-Buffered Saline (PBS):  137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, and 2 mM KH2PO4 in dH20.   
PBS- with Tween20 (PBST): PBS plus 0.2% Tween 20. 
Western Blot Stripping Buffer:  100 mM Beta-Mercaptoethanol, 62.5 mM Tris-HCl, 
and 2 % SDS.  Beta-Mercaptoethanol was added fresh. 
Whole cell lysate isolation 
Lysates were prepared from adherent cells by removing spent media, 
washing once with 1 ml of 1x PBS, and releasing cells from tissue culture plate 
with a sterile cell lifter. Cells were collected in 1.5 ml microcentrifuge tube and 
resuspended whole cell lysis buffer.  Volume of lysis buffer was contingent on cell 
density.  Lysates were incubated on ice for 1 hour then centrifuged at 16,000 xg 
for 5 minutes to pellet the cellular debris.  Lysates were transferred to a new 
microcentrifuge tube and stored at -80 °C. 
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General western blot procedure 
Whole cell lysates and protein size ladder were run on SDS-PAGE at 100 
volts in 1x Tris-Glycine Running Buffer (Mini-Protean, Bio-Rad).  Protein was 
transferred onto polyvinylidene difluoride (PDVF) membrane, which had been 
treated, for at least 1 minute, with methanol to pre-wet the hydrophobic PDVF 
membrane.  Gels were transferred onto membranes at 100 volts for 1 hour and 
30 minute with freshly prepared Transfer Buffer (Mini-Trans Blot Electrophoretic 
Transfer Cell, Bio-Rad).   
Membranes were blocked in for 1 hour at room temperature or overnight 
at 4 °C.  Membranes were probed with specific primary antibody (Table 5) in 
blocking solution for 2 hours at room temperature or overnight at 4 °C.  
Membranes were washed 3 times in PBST, and then incubated for one hour with 
secondary antibody (Table 5) in blocking solution.  After washing with PBST 3 
times, and one wash with PBS; membranes were treated with 2ml of 
chemiluminescence reagent (ECL Plus or Prime, GE Healthcare) per blot for 5 
minutes and exposed to film. 
Western Blots:  RON and β-actin 
Whole cell lysates were run on 8% SDS-PAGE.  For tissue-resident 
macrophage lysates, double or triple the normal volume was loaded onto the gel 
(“normal” loading volume: 9μl of lysate, 9μl of 2x SDS dye, and 2μl DTT).  Half of 
the volume was loaded into the gel, the gel was allowed to run for 5 minute to 
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ensure the sample had migrated into the gel, but remained in the stacking gel; 
after which the remaining volume was loaded.   
Following transfer, the blot was cut at the 72 kilodaltons (KDa) band.  The 
RON heterodimer runs at 160 KDa and β-actin runs at 55 KDa.  Cutting the blot 
precluded the need for stripping and the reprobing for β-actin loading control.  
Blots were probed overnight with rabbit anti-human RON antibody (Santa Cruz 
Biotechnology)   or mouse anti-human actin (Sigma-Aldrich), in 3 % NFM, at 
concentrations of 1:5,000 and 1:10,000 respectively. Following wash with PBST, 
blots were probed with HRP anti-rabbit and HRP anti-mouse, in 3 % NFM, at 
concentrations of 1:10,000 and 1:20,000 respectively.   
Western Blots:  p21, anti-Flag, and β-actin  
Whole cell lysates were run on 6 % SDS-PAGE.  Blots were probed 
overnight with mouse anti-human p21 antibody (Santa Cruz Biotechnology) in 
3% BSA, at a concentration of 1:5,000. Following wash with PBST, blots were 
probed with HRP anti-mouse, in 3 % BSA, at a concentration of 1:20,000.  
Alternatively, the blot could be stored 1x PBS at 4°C. 
Blots were placed in sealable pouch with ~10ml of western blot stripping 
buffer, and incubated at 56°C water bath for 45 minute - 1 hour, shaking every 15 
minutes.  Blots was washed in 1x PBS.  
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Blots were reprobed with mouse anti-human Flag antibody (Sigma-
Aldrich) at a concentration of 1:10,000 in 3 % NFM.   Following wash with PBST, 
blots were probed with HRP anti-mouse, in 3 % NFM, at a concentration of 
1:20,000.  Alternatively, the blot could be stored 1x PBS at 4°C. 
The stripping procedure was repeated and blots were reprobed with 
mouse anti-human β-actin antibody, at a concentration of 1:10,000 in 3 % NFM.   
Following wash with PBST, blots were probed with HRP anti-mouse, in 3 % NFM, 
at a concentration of 1:20,000.   
Flow cytometry 
 Tissue-resident macrophages were harvested at day 7 with an EDTA 
solution (Versene, Invitrogen) and minimal agitation to release adherent cells.  
Cells were gently pelleted by centrifuging at 300 xg for 10 minute at 4 °C.  Cells 
were washed in cold PBS and 0.5-1 x 106 cells in 90 μl buffer of PBS plus 
0.5%BSA and 2mM EDTA and allotted to a 1.5ml microcentrifuge tube / antibody.  
10μl FcR Blocking Reagent (Miltenyi Biotec GbmH) was added to each tube, and 
incubated for 10 minute at 4°C.  Without removing FcR Blocking Reagent, cells 
were stained with antibodies for 30 minute on ice.  Cells were washed in 2x PBS 
plus 0.5%BSA and 2mM EDTA and centrifuged at 300 xg for 10 minute at 4 °C.  
Samples requiring a secondary antibody were stained with antibodies for 30 
minute on ice, and then washed in 2x PBS plus 0.5%BSA and 2mM EDTA and 
centrifuged at 300 xg for 10 minute at 4 °C.  Following washes, cells were fixed in 
 
92 
 
2% paraformaldehyde and analyzed using the BD Biosciences FACScan at the 
Flow Core Facility at Boston Medical Center.  Histograms were gated on 
macrophage populations determined by forward scatter/side scatter plots, to 
exclude dead cells.  Gated population represented approximately 70% of total 
events.   
HIV-p24 Gag enzyme-linked immunosorbent assay (ELISA) 
Cell free supernatants were collected from infected and uninfected control 
cell cultures.  HIV-p24 Gag in the supernatant was analyzed using ELISA (Perkin 
Elmer).  Supernatants were diluted in 1x PBS at a dilution of 1:1,000 and 1:2,000.  
Two hundred ng/ml stock HIV-p24 standard (Perkin Elmer) was diluted to 100, 
50, 25, and 12.5 pg/ml in 1x PBS.  Twenty μl 5% Triton X were added to antibody 
pre-coated HIV-p24 Gag ELISA plates (Perkin Elmer).  Two hundred μl of diluted 
supernatants and HIV p24 standard were loaded, and plates were incubated at 
37 ºC for 2 hours.  Plates were washed six times with 250 μl 1x wash buffer 
(phosphate buffer with 1% Tween-20).  After each wash, plate was firmly blotted 
against absorbent surface to remove all liquid.  One hundred μl of rabbit 
polyclonal anti-p24 detector antibody were added to each well, and the plates 
were incubated at 37 ºC for 1 hour.  Plates were washed six times as before.  
100 μl of streptavidin(SA) horseradish peroxidase (HRP) working solution (SA-
HRP 100 fold concentrate in citrate buffer with BSA and detergent diluted 1:100 
in SA-HRP PBS plus BSA and 0.05% Tween-20 diluent) were added to each 
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well, plates were incubated at room temperature for 1 hour.  Plates were washed 
six times as before.  One o-Phenylenediamine dihydrochloride (OPD) tablet was 
added per 11 ml of substrate diluent (citrate buffer with 0.03% hydrogen 
peroxide), and 100 μl was added to each well.  To stop the reaction, 100 μl of 
stop solution (4N sulfuric acid) was added to each well.   
Plates were read at 492 nm on Spectramax 340 PC using Softmax Pro 
software, and the p24 value was extrapolated from the HIV-p24 standard curve. 
Statistical Analysis 
Power Analysis 
Power analysis was completed to determine the number of animals 
required to confidently state significant differences at a 5% confidence level.  
Using the existing data set, the t statistic and t distribution table were used to 
estimate the confidence level for sample sizes 1-10.  
A = control mean (ex:  uninfected macaques) 
B= experimental treatment group mean (example infected macaques day 42) 
n = sample size 
df=degrees of freedom = n-1 
SE=√σ1/n1 - σ2/n2  (assume σ1 = σ2 and assume n1=n2)  therefore SE=√σ/n      
t = A - B / SE  
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Student’s T test 
Statistical analysis was performed with Excel using a student’s T test, 2-
tailed distribution and assuming equal variances.  Confidence levels of at least 
0.05 were deemed significant. 
Non-parametric Wilcoxon-Mann-Whitney test 
While student’s T test was used as the primary statistical analysis of 
significance, a non-parametric analysis was also performed, and results were 
comparable to those calculated using the student’s T test.  The Wilcoxon-Mann-
Whitney test does not assume a normal population distribution.  The Wilcoxon-
Mann-Whitney table and U statistic are used to determine the confidence level.  
Confidence levels of at least 0.05 were deemed significant. 
n = data set 1 sample size 
n’ = data set 2 sample size 
Y1 = data set 1 (ex:  uninfected macaques) 
Y2 = data set 2 (example infected macaques day 42) 
K1 = Sum of observations data set 2 values smaller than each data set 1 value 
K2 = Sum of observations data set 1 values smaller than each data set 2 value 
U = The larger K value  
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Pearson’s correlation coefficient 
The Pearson’s correlation coefficient (r) was calculated comparing RON 
real time RT-PCR data to the presence (1) or absence (0) of CNS disease 
lesions and the SIV viral load in the basal ganglia (SIV RNA copy equivalent / μg 
brain RNA).  Viral load data was log transformed to fit a linear regression. The r 
statistic was calculated using the “CORREL” formula in Excel.  The t statistic was 
calculated.  The t-distribution was used to determine the p-value for the 
correlation coefficient.  The t-distribution was calculated using the “T.DIST” 
function in Excel with n-2 degrees of freedom, and a 2-tailed distribution.  .   
r =CORREL(data set 1,data set 2) 
t= r(√n-2)/√1-r2 
t distribution = T.DIST(t statistic, n-2 degrees of freedom, 2 tail distribution 
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CHAPTER 1.  RON RECEPTOR TYROSINE KINASE, A NEGATIVE 
REGULATOR OF INFLAMMATION, IS DECREASED DURING SIMIAN 
IMMUNODEFICIENCY VIRUS ASSOCIATED CENTRAL NERVOUS SYSTEM 
DISEASE 
Parts of this chapter were published previously in the The Journal of Immunology, 
2013, 191: 4280–4287.  Daniele C. Cary, Janice E. Clements, and Andrew J. 
Henderson.  Copyright 2013. The American Association of Immunologists, Inc. 
1.1.  Rationale 
Previous work from our laboratory has shown that RON represses HIV-1 
transcription (Klatt et al., 2008; Lee et al., 2004), but the receptor is targeted for 
degradation by HIV-1-Tat (Kalantari et al., 2008). Furthermore, expression of 
RON is reduced in post-autopsy brain tissue of patients with HIV-1-associated 
encephalitis (Lee et al., 2004), indicating that a loss of this protective mechanism 
results in brain inflammation.  However, to appreciate its role in HIV-1 
pathogenesis, it is critical to evaluate the function and expression of RON during 
the course of infection in primary tissue-resident macrophages and not solely as 
a terminal endpoint.  We propose that signaling through RON limits HIV-1 
transcription, establishing reservoirs of infected tissue-resident macrophages. 
With time, possibly as a result of chronic inflammation and/or HIV-1 infection, 
RON expression is decreased and inflammation is exacerbated, resulting in a 
microenvironment which favors HIV-1 transcription, virus spread and tissue 
 
97 
 
damage. In this study we utilize an established macaque infection model for 
accelerated SIV-associated CNS disease (Clements et al., 2008) as well as a 
primary tissue-resident macrophages, to investigate the relationship between 
RON, HIV-1 replication, and HIV-1-associated inflammation.  
1.2   RON is inversely correlated to CNS disease severity in parietal cortex 
of pigtail macaques. 
Reduced RON expression has been observed in brain tissue from 
HIV/AIDS (Lee et al., 2004) and multiple sclerosis patients (Tsutsui et al., 2005), 
suggesting a correlation between inflammatory insult in the brain and the 
absence of RON.  To gain a better understanding of RON expression in vivo 
during disease progression, we utilized a temporal model of SIV-associated CNS 
inflammation in pigtail macaques which recapitulates HIV-1 CNS pathogenesis 
including encephalitis and behavioral changes (Clements et al., 2011; Clements 
et al., 2008).  Macaques were infected with two SIV variants: an immune-
suppressive variant (SIV/Delta B670) and a neurovirulent variant (SIV/17E-Fr) 
(Babas et al., 2006).  Within three months of SIV infection, 90% of infected pigtail 
macaques develop inflammatory lesions (Clements et al., 2008), providing a 
consistent, accelerated model to study the dynamic events contributing to SIV-
associated CNS disease (table I). 
Using real-time RT-PCR, RON mRNA was detected in the brains of 
uninfected and SIV infected pigtail macaques (Fig. 13A).  During acute SIV 
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infection, RON expression was initially reduced by 75% compared to uninfected 
control RON mRNAs, but rebounded within a few days to uninfected levels 
before declining again to 60% below controls by day 21 (Fig. 13A).  Repression 
of RON expression continued through the asymptomatic and into the chronic 
stage of infection. At days 56 and 84 post infection, when CNS disease lesions 
are evident in 90% of the animals (32), we observed a >60% decrease in RON 
expression compared to uninfected controls (Fig. 13A).  RON expression 
negatively correlated (Pearson’s correlation coefficient of r= -0.77) with CNS 
disease lesions during chronic infection, as scored by the presence of 
perivascular macrophage cuffs (Fig. 13C).  This correlation (r = -0.80) was 
particularly evident at day 42 (Fig. 13D), a time point in which we observed 
variable disease symptoms and RON expression.  Day 42 animals, with no 
indices of CNS disease, expressed significantly more RON than animals that 
showed evidence of mild to severe CNS lesions, which expressed 60% less RON 
(Fig. 13B). Comparing RON expression with viral load data also showed a 
negative correlation between SIV RNA levels in the brain and RON (r= -0.48; Fig. 
13C); animals with low viral loads had higher RON expression than animals with 
elevated viral loads.  This correlation (r = -0.80) was especially apparent at day 
42 (Fig. 13D). 
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Figure 13.  RON is inversely correlated to CNS disease severity in parietal 
cortex of pigtail macaques. (A) Quantitative real time RT-PCR analysis for 
RON normalized to β-actin was performed using cDNA from parietal cortex 
isolated following sacrifice of infected and uninfected control macaques at the 
indicated times. Quantitative real time RT-PCR analysis of RON transcripts was 
normalized to β -actin, and expression was calculated based upon RON and β -
actin plasmid DNA standard curves.  Each point represents a different animal. (B) 
Presence of CNS disease lesion was determined based upon the presence of 
perivascular cuffs of macrophages in tissue samples, as previously described.  
RON expression, presented above, is shown here in relationship to disease 
severity at each stage of the infection (*p<0.05, **p<.001). (C)  Pearson’s 
correlation coefficients (r) were calculated using RON expression, presented 
above, and presence of CNS disease lesions (top panel) or basal ganglia viral 
load (SIV RNA copy equivalent/ μg brain RNA) (bottom panel) in SIV infected 
macaques at days 42, 56, and 84 post infection (*p<0.05, **p<.001). The best fit 
least squares regression line is shown.  Each point represents a different animal. 
(D) Pearson’s correlation coefficients (r) were calculated using RON expression, 
presented above, and presence of CNS disease lesions or basal ganglia viral 
load (SIV RNA copy equivalent/ μg brain RNA) in SIV infected macaques at d 42 
post infection. (**p<.001) RON expression was used to calculate correlation 
coefficient. The best fit least squares regression line is shown.  Each point 
represents an individual animal. 
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1.3  Interleukin 12-p40, TNF α and Arginase-1 expression correlated with 
RON expression. 
RON regulates inflammation in part by inhibiting transcription of cytokines 
such as IL-12 p40 and TNFα (Morrison et al., 2004; Ray et al., 2010) and 
promoting the expression of enzymes required for wound repair including Arg-1 
(Morrison and Correll, 2002; Sharda et al., 2011).  Moreover, Arg-1 competes 
with inducible nitric oxide synthase (iNOS) for the substrate, L-arginine, thereby 
indirectly acting as an anti-inflammatory factor (Chang et al., 1998).  We would 
predict that reducing RON expression in the CNS of SIV infected macaques 
would lead to an increase in inflammatory cytokines normally repressed by RON.  
We observed a 5 fold increase in IL-12 p40 expression at day 42 post infection 
as well as significantly elevated expression of IL-12 p40 at day 84 (Fig. 14A).  
TNFα expression was also significantly elevated compared to uninfected controls 
at days 42 and 84 post infection (Fig. 14B).  During chronic SIV infection, Arg-1 
expression in the CNS was reduced by 70% compared to expression in 
uninfected controls (Fig. 14C).  The overall increase in IL-12 p40 and TNFα and 
decrease in Arg-1 corresponded with reduced RON expression observed at 
these time points (Fig. 13A).  Taken together, these results are consistent with 
RON having a protective role in the brain and that compromising its expression 
and function by SIV infection exacerbates inflammation. 
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Figure 14.  Arg-1, Interleukin 12 p40, and TNF α expression correlated with 
RON expression. (A-C) Quantitative real time RT-PCR analysis for (A) Arg-1, 
(B) IL-12 p40, and (C) TNFα expression normalized to β-actin expression was 
performed using cDNA from parietal cortex. Relative expression was determined 
using uninfected control expression as a calibrator and the 2-ddCT method. 
(*p<0.05, **p<.001).  A representative group of animals at each day post SIV 
infection was used for cytokine analysis (3 of 6 uninfected animals, 4 of 9 
animals at day 42, and 6 of 9 animals at day 84).  Each point represents a 
different animal. 
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1.4  RON is expressed and functional on human tissue-resident 
macrophages. 
To test if RON directly impacts HIV-1 transcription we utilized human 
primary tissue-resident macrophages derived from tonsil (Kawaguchi et al., 1988; 
Stent et al., 2002; Willson et al., 1976).  Tonsil tissue is accessible and tonsil 
derived macrophages are susceptible to HIV-1 infection (Glushakova et al., 1995; 
Jayakumar et al., 2005). Furthermore, human tonsil tissue-resident macrophages 
have been a useful model for studying HIV-1 infection of tissue-resident 
macrophages and the tonsil has been proposed as a potential reservoir for HIV-1 
(Cavert et al., 1997; Crowe et al., 2003; Dinoso et al., 2009; Pantaleo et al., 
1993; Thompson et al., 2011).  Mononuclear cells were isolated from tonsils, and 
allowed to mature into macrophages on plastic for 7 days.  These cells express 
RON (Fig. 15A) and are positive for surface CD14 expression (Fig. 15B), as well 
as CD16, mannose receptor CD206 and CXCR4 and CCR5 (Fig. 15B), markers 
consistent with tissue-resident macrophages. Pretreatment with MSP, the ligand 
for RON, followed by stimulation with LPS and IFNɣ, resulted in a 70% decrease 
in inducible IL-12 p40 expression (Fig. 15C). Additionally, a 5 fold increase in Arg-
1 expression was evident in the tissue macrophages pretreated with MSP (Fig. 
15C).  These data suggest that we have enriched for tissue-resident 
macrophages that express functional RON thus providing a tractable primary cell 
model to examine the ability of RON to influence HIV-1 replication.   
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Figure 15.  RON is expressed and functional on human tissue-resident 
macrophages.   (A) Whole cell lysates from were prepared from human tissue-
resident macrophages enriched from tonsils from two donors as described in 
methods, were run on 8% SDS-PAGE.  Membranes were probed with antibodies  
to human RON or human β-actin.  (B) Tissue-resident macrophages were treated 
with FcγR blocking reagent and stained with fluorescently labeled antibodies 
against CD14 (MFI=54.40), CXCR4 (MFI=55.19), CCR5 (MFI=33.45), CD16 
(MFI=19.08), and CD206 (MFI=19.77) and appropriate isotype controls.  Stained 
cells were fixed in 2% paraformaldehyde and analyzed on the BD FACscan. (C) 
Quantitative real time RT-PCR analysis for Arg-1 and IL-12 p40 expression, 
normalized to β-actin expression, was performed using cDNA from tissue-
resident macrophages.  Relative expression was determined using uninfected 
 
105 
 
control expression as a calibrator and the 2-ddCT method.  Clear bars represent 
unstimulated conditions and black bars represent cells stimulated with LPS 
(10μg/ml) and IFNγ (1000U/ml) for 4 h. (*p<0.05, **p<.001).  Data is 
representative of 3 experiments with triplicate stimulations from at least 3 donors. 
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1.5  MSP limits HIV-1 replication in human tissue-resident macrophages. 
Tissue derived macrophages were infected in vitro with BaL-HIV-1, a 
CCR5 tropic virus, the CXCR4 tropic NL4.3 or HIV-1 NL4.3 pseudo-typed with 
VSV-G envelope.  Following 48 h treatment of infected cells with MSP, HIV-1 
replication was reduced by 65% compared to untreated infected cells at day 3 
post-infection, as measured by p24 ELISA (Fig. 16A).  HIV-1 transcription was 
also significantly reduced by MSP regardless of envelope used for infection (Fig. 
16 C-D) consistent with previous reports that RON limits provirus transcription 
(Klatt et al., 2008; Lee et al., 2004). 
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Figure 16.  RON limits HIV replication in human tissue-resident 
macrophages. (A-B)Tissue-resident macrophages were infected with NL4.3 
HSA psuedotyped with VSVG overnight.  Cells were washed twice with PBS, and 
provided fresh media +/- MSP (100ng/ml). Cell free supernatants and RNA were 
collected 3 days post infection. (A)  p24 gag in the supernatant was measured by 
ELISA. (B) Quantitative real time RT-PCR analysis for HIV-1 elongated 
transcripts, normalized to β-actin expression, was performed.  Relative 
expression was determined using uninfected control expression as a calibrator 
and the 2-ddCT method. (C-D) Tissue-resident macrophages were infected with (C) 
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NL4.3 and (D) BaL overnight.  Cells were washed twice with PBS, and provided 
fresh media +/- MSP (100ng/ml). RNA was collected 3 days post infection. 
Quantitative real time RT-PCR analysis for HIV-1 elongated transcripts, 
normalized to β-actin expression, was performed.  Relative expression was 
determined using uninfected control expression as a calibrator and the 2-ddCT 
method.  (*p<0.05, **p<.001).  Data is representative of 3 experiments with 
triplicate infections and at least 3 donors. 
 
 
109 
 
 
1.6  RON limits HIV-1 transcription in human tissue-resident macrophages. 
It has been suggested that RON signals constitutively in the absence of 
ligand (Wei et al., 2005b) and this constitutive signaling contributes to a partial 
barrier to HIV-1 replication (Klatt et al., 2008; Lee et al., 2004).  RON expression 
was knocked down in tissue-resident macrophages to determine if RON, 
independent of MSP treatment, inhibited HIV-1.  Following 24 hour infection, 
RON expression was knocked down with siRNA and 48 hours post-knockdown, 
an 88% reduction in RON expression was observed at the mRNA level which 
was validated by immunoblots (Fig. 17A & B).  A 2 fold increase in HIV-1 p24 was 
detected following RON knockdown (Fig. 17C). Consistent with the observation 
that RON acts post-entry and at the level of HIV-1 transcription regulation, 
diminishing RON expression increased HIV transcription regardless of the 
envelope used (Fig. 17D-E). Taken together these data indicate that RON limits 
HIV-1 in the presence and absence of its ligand in primary tissue-resident 
macrophages. 
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Figure 17.  Depletion of RON results in increased HIV replication in human 
tissue-resident macrophages. (A) Tissue-resident macrophages were infected 
with NL4.3 HSA psuedotyped with VSVG overnight.  Cells were washed twice 
with PBS. and transfected with RON or control siRNA using Mirus reagent for 48 
h. RNA was collected 3 days post infection.  Qualitative real time RT-PCR 
analysis of RON transcripts was normalized to β-actin, and expression was 
calculated based upon RON and β-actin plasmid DNA standard curves. (B) 
Tissue-resident macrophages were transfected with RON or control siRNA using 
Mirus reagent for 48 h. Whole cell lysates were run on 8% SDS-PAGE.  
Membranes were probed with antibodies to human RON or human β-actin. (C-D) 
Tissue-resident macrophages were infected with (C) NL4.3 HSA psuedotyped 
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with VSVG and (D) BaL overnight.  Cells were washed twice with PBS. and 
transfected with RON or control siRNA using Mirus reagent for 48 h. RNA was 
collected 3 days post infection. Quantitative real time RT-PCR analysis for HIV-1 
elongated transcripts, normalized to β-actin expression, was performed.  Relative 
expression was determined using uninfected control expression as a calibrator 
and the 2-ddCT method. (*p<0.05, **p<.001).  Data is representative of 3 
experiments with triplicate infections and at least 3 donors. 
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1.7  HIV-1 infection reduces RON expression in human tissue-resident 
macrophages.   
Our in vivo data strongly suggests that SIV infection causes a decrease in 
RON expression (Fig. 13A); however we are unable to determine if expression is 
directly regulated by SIV or if diminished RON expression reflects recruitment of 
inflammatory, RON negative, macrophages.  Previous work from our lab 
indicated that HIV-1 directly down-regulates RON expression in cell lines 
overexpressing RON (Kalantari et al., 2008).  Using primary tissue-resident 
macrophages, we examined whether HIV-1 was directly targeting RON.  RON 
expression in tissue-resident macrophages was monitored by RT-PCR at 21 days 
post-infection. HIV-1 infection decreased RON mRNA by 87% compared to 
uninfected controls (Fig. 18). Consistent with a lack of functional RON being 
expressed on these cells, MSP treatment did not affect HIV-1-mediated 
repression of RON expression (Fig. 18).  Therefore, HIV-1 directly down-
regulates RON expression, possibly promoting efficient HIV-1 replication.  
However we cannot rule out the contribution of indirect effects on RON 
expression by inflammatory mediators induced by HIV.   
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Figure 18.  Prolonged HIV infection reduces RON expression in human 
tissue-resident macrophages. Infected tissue-resident macrophages were 
infected with NL4.3 HSA psuedotyped with VSVG overnight.  Cells were washed 
twice with PBS, and provided fresh media +/- MSP (100ng/ml). RNA was 
collected 21 days post infection.  Qualitative real time RT-PCR analysis of RON 
transcripts was normalized to β-actin, and expression was calculated based upon 
RON and β-actin plasmid DNA standard curves. (*p<0.05). Data is representative 
of 3 experiments with triplicate infections and 2 donors. 
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1.8  Discussion. 
The elevated levels of inflammatory cytokines observed in the CNS upon 
chronic HIV-1 infection suggest that control of the cytokine network is 
compromised.  We have previously demonstrated that RON, which limits 
macrophage inflammatory activities, is reduced in brains of end stage HIV-1-
infected individuals with evidence of encephalitis (Lee et al., 2004). In this study, 
we have used a progressive macaque SIV CNS disease model to show that over 
time RON expression is decreased in SIV-infected macaques and that this 
inversely correlates with inflammatory cytokine expression and brain disease. 
Furthermore, in vitro studies using primary tissue-resident macrophages confirm 
that RON initially limits HIV-1 transcription but over the course of infection 
receptor expression is decreased.   
The macaque SIV infection model provided an opportunity to explore 
when RON expression is decreased during infection and whether this correlates 
with other indicators of inflammation. The macaque model has been well 
characterized (Clements et al., 2011; Clements et al., 2008) and it has been 
shown that the macaques develop similar symptoms in approximately 80 days to 
the HIV-1 associated disease which takes years to develop in humans.  In both 
macaques and humans, elevated levels of cytokines, including TNFα and IL-6 
(Witwer et al., 2009; Yadav and Collman, 2009; Zink et al., 1999), as well as the 
development of encephalitic lesions are observed. It is at approximately at day 
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42 when the SIV infected macaques begin to present CNS disease symptoms 
and exhibit changes in the expression cytokines and immunomodulatory 
molecules including; IL-12 p40,TNFα, IFNβ IL6, IL-10, MHC class II, MCP-1, 
C/EBPβ and HIV-1 RNA (Barber et al., 2006; Dudaronek et al., 2007; Ravimohan 
et al., 2010; Witwer et al., 2009). Despite the variability in RON expression at this 
day 42 transition to chronic disease, there is a significant inverse correlation 
between RON, viral load and disease in the CNS. The overall dysregulation in 
the inflammatory microenvironment during chronic infection may reflect the 
compromised activity of regulatory factors, such as RON, which are upstream of 
inflammatory cytokines such as IL-12 p40 (Morrison et al., 2004) and TNFα 
(Nikolaidis et al., 2010) transcription, and limit their expression. 
Arg-1 counters inflammation by mediating tissue repair as well as 
competing with iNOS for the substrate, L-arginine (Chang et al., 1998).  Arg-1 is 
decreased in the brains of chronically SIV infected macaques consistent with 
RON being upstream of Arg-1 and regulating its transcription (Morrison and 
Correll, 2002; Sharda et al., 2011).  Importantly, we confirmed that human tissue-
resident macrophages are capable of producing Arg-1.  Arg-1 has been defined 
as a marker for murine alternative  macrophages, however, it has been reported 
that human macrophages do not express arginase  based on transcription 
profiling of IL-4 or IL-13 polarized monocyte derived macrophages (Martinez et 
al., 2006; Scotton et al., 2005). Recent studies have challenged this original 
observation; peripheral monocytes isolated following trauma injury (Ochoa et al., 
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2001) and surgery (Tsuei et al., 2001), and macrophages found in tuberculosis 
granulomas (Mattila et al., 2013; Munder et al., 2005; Pessanha et al., 2012) 
express Arg-1.  Our data are consistent with these latter observations and 
suggest that RON is expressed on a spectrum of macrophage subsets.   
HIV-1 infects resident macrophage populations in the brain, including 
perivascular macrophages and microglia (Davis et al., 1992; Palmer et al., 1994); 
however, it is difficult to find primary or tissue culture systems that mimic CNS 
cells, therefore, we used tonsil derived macrophages as a cellular surrogate for 
tissue-resident macrophages. Although tissue macrophage populations are 
phenotypically and functionally heterogeneous, tonsil tissue is accessible, has 
been used as an in vitro model for human tissue-resident macrophages, is 
susceptible to HIV-1 infection, and represents a potential HIV-1 sanctuary. Tonsil 
macrophages preserved characteristics of tissue-resident macrophages 
(Kawaguchi et al., 1988; Stent et al., 2002; Willson et al., 1976) and supported 
HIV-1 replication (Glushakova et al., 1995; Jayakumar et al., 2005), indicating 
that our culture conditions preserved the tissue-resident macrophage phenotype. 
Furthermore, RON was functional, regulating the expression of LPS-induced IL-
12 p40 and Arg-1. 
Using the tissue-resident macrophage in vitro model, we demonstrate that 
RON initially inhibits HIV-1 transcription and following prolonged infection, HIV-1 
infection decreases RON expression, supporting our observations in the human 
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(Lee et al., 2004), macaque and cell lines (Kalantari et al., 2008) that HIV-1 
infection leads to a down regulation of RON.  We have previously shown using 
U937 cells overexpressing RON from a heterologous promoter that HIV-1 Tat is 
able to target RON protein for degradation with no significant effect on RON 
transcription (Kalantari et al., 2008). In both the SIV model and the in vitro 
primary cell models, RON was diminished at the level of transcription, 
demonstrating that HIV-1 targets RON expression and function through multiple 
mechanisms. 
We propose a model in which RON collaborates with other anti-
inflammatory molecules, to protect tissue-resident macrophages and tissues, 
including the CNS, from excessive inflammation.  However, this control is not 
absolute, and eventually HIV-1 infection circumvents these barriers to 
inflammation.  By down regulating inhibitory molecules like RON, virus replication 
is enhanced, inflammatory cytokines expression is increased, and protective 
molecules such as Arg-1 are diminished, ultimately contributing to cell death and 
end organ tissue damage. 
1.9  Future directions 
 Future experiments will utilize the tonsil derived macrophages to gain an 
understanding into mechanisms that regulate inflammation, HIV, and RON 
expression in tissue-resident macrophages.   
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 HIV infection has been associated with decreased expression of 
immunomodulatory proteins, including:  CD4, MHC class I, (Emerman and 
Malim, 1998), and RON (Kalantari et al., 2008; Lee et al., 2004).  Previous work 
has demonstrated that HIV Tat targets RON for proteasome mediated 
degradation (Kalantari et al., 2008).  The above data suggests that RON mRNA 
expression is also regulated by HIV infection.  The mechanism by which HIV 
represses RON transcription is unclear.  Using RON expressing tonsil derived 
macrophages we can address which HIV proteins are responsible for the 
repression of RON transcription and identify cis-elements in the RON promoter 
that control RON expression in the context of HIV infection (Angeloni et al., 2000; 
Del Gatto et al., 1995). 
HIV-infected individuals are highly susceptible to secondary opportunistic 
infections.  We hypothesize that HIV infection will result in a loss of mechanisms 
that control inflammation in tissue-resident macrophages, thereby making them 
more vulnerable to secondary infections pathogens that target the oral and 
genital mucosa, sites of primary HIV infection (Bafica et al., 2004; Mbopi-Keou et 
al., 2002).  We hypothesize that HIV infection of tissue resident macrophages 
contributes directly to this compromise in oral immunity and enhanced host 
sensitivity to periodontal pathogens.  The oral pathogen Porphyromonas 
gingivalis reactivates HIV in infected macrophage cell models (Imai et al., 2009; 
Imai et al., 2012).  Using the primary tonsil macrophages, we will explore how 
HIV alters the functional macrophage response to Porphyromonas gingivalis.  
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We will examine cytokine expression, bactericidal activity, phagocytic function, 
and expression of PRR.  HIV infection results in an increase in TLR 2 and 4 
expression on MDM in vitro and in vivo (Hernandez et al., 2012; Lester et al., 
2008), which suggests an increase in these factors upon HIV infection of tissue-
resident macrophages.  Our initial studies with primary human tonsil 
macrophages in vitro have failed to demonstrate significant changes in TNFα and 
IL-12 p40 following HIV infection or RON knockdown (data not shown) though 
further more exhaustive cytokine profiling needs to be performed.   
RON signaling inhibits HIV transcription through regulation of 
transcriptional initiation, elongation, and chromatin remodeling.  Previous studies 
in U937 and HEK 293T overexpressing RON indicated that the RON docking site 
domain is dispensable in RON MSP-independent signaling (Wei et al., 2005b) 
while both kinase and docking site motifs are required for the inhibition of HIV 
transcription (Klatt et al., 2008).  Mutations have been engineered into critical 
tyrosines providing us tools to map critical functional domains of RON (Wei et al., 
2005a; Wei et al., 2005b) as well as signaling cascades that potentially repress 
HIV provirus transcription.  
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CHAPTER 2.  THE CYCLIN-DEPENDENT KINASE INHIBITOR P21 LIMITS HIV 
TRANSCRIPTION IN HIV+ ELITE CONTROLLERS 
 
2.1  Rationale. 
p21, also known as CIP1/WAF1, is regulated by the tumor suppressor p53 
and inhibits the function of kinases necessary for cell cycle progression, thereby 
inducing G1 arrest (Davies et al., 2013; Mbopi-Keou et al., 2002).   A cohort of 
HIV-infected elite controllers have elevated expression of p21 compared to HIV+ 
progressors and HIV seronegative individuals (Buzon et al., 2011; Chen et al., 
2011).   
HIV-infected elite controllers are rare HIV+ individuals who control the 
progression of disease.  These individuals have viral loads below detectable 
limits and normal CD4+ T cell counts, for at least 7 years following infection, in 
the absence of anti-retroviral therapy (Autran et al., 2011; Chun et al., 2013; 
Eyzaguirre et al., 2013; O'Connell et al., 2009).  Understanding endogenous 
mechanisms within these individuals which contribute to their continued health 
could identify novel treatment strategies.   
p21 binds the HIV pre-integration complex and blocks the integration of 
provirus in primitive hematopoietic stem cells and T cells from elite controllers 
(Buzon et al., 2011; Zhang et al., 2007a).  Additionally, a cohort of HIV+ elite 
controllers with elevated p21 have limited HIV transcription (Chen et al., 2011).  
Inhibiting p21 with chemical inhibitors or p21 siRNA knockdown increases Pol II 
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serine 2 phosphorylation and enhances HIV transcriptional elongation (Chen et 
al., 2011).   
Our lab has previously shown that the NELF inhibits HIV transcription by 
preventing transcriptional elongation (Natarajan et al., 2013; Zhang et al., 
2007b).  p21 inhibits CDK9, the enzymatic subunit of the P-TEFb (Chen et al., 
2011).  CDK9 phosphorylates both the serine 2 residue of the CTD of Pol II and 
NELF to facilitate the release of the polymerase from promoter proximal pausing, 
allowing productive elongation to occur (Bres et al., 2008; Fujinaga et al., 2004; 
Zhou and Yik, 2006).   We overexpressed p21 in human seronegative CD4+ T 
cells, and demonstrated that HIV transcription is inhibited.  Furthermore, HIV- 
infected CD4+ T cells from elite controllers have elevated levels of NELF 
associated with the HIV LTR, while Pol II binding was not altered; suggesting p21 
limits HIV transcriptional elongation. 
2.2  Development of retroviral p21 construct. 
To explore the mechanisms by which p21 represses HIV transcription, we 
generated a p21 lentiviral expression vector. The wild-type p21 sequence 
contains a flag sequence at +89 and single BamHI restriction enzyme site at 
+629 (Fig. 19A).  An additional BamHI restriction enzyme site was created via 
PCR amplification and a double mismatch in the wild type p21 sequence (Fig. 
19B).  The addition of this site allowed the p21 construct to be ligated into a 
single BamHI site in the flap-Ub promoter-GFP-WRE (FUGW) retroviral vector 
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(Fig.19A).  Transfection of FUGW p21-flag into HEK 293T cells confirmed 
expression of p21 and flag-tag (Fig. 19C).   
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Figure 19.  Flag-tagged p21 is subcloned into the pFUGW retroviral vector.  
(A) Using a PCR strategy, an additional BamHI site was added to the beginning 
of the insert prior to the flag sequence through a mismatch of two base pairs.  
The PCR primers recognize the sequence upstream +1-18 and +650-670 
(rectangle).  In addition to the added BamHI site, a second BamHI site is present 
in the wild-type sequence at +629 (underlined).  The BamHI fragment retains the 
flag sequence (high-lighted) and NdeI site (oval) used to verify correct orientation 
of the p21 insert.  (B)  The forward primer sequence contains a double mismatch 
of the wild-type sequence to insert a BamHI site into the wild-type flag-p21 
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sequence.  (C) HEK 293T cells were transiently transfected with pFUGW or 
pFUGW-flag-p21 by CaPO4 transfection and whole cell lysates were collected 24 
hours post transfection. Whole cell lysates were run on 10% SDS-PAGE.  
Membranes were probed with antibodies to human p21, then stripped and 
reprobed with anti-flag and human β-actin. 
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2.3  Overexpression of p21 limits HIV transcription. 
We utilized the retroviral vector system to overexpress p21 in human CD4+ 
T cells.  Spinoculation of FUGW-p21-flag into human primary CD4+ T cells 
resulted in over-expression of p21 at the protein level (Fig. 20A).  HIV infection of 
human primary CD4+ T cells, following 24 hour overexpression with FUGW p21-
flag resulted in a 96% decrease in HIV promoter proximal transcripts (Fig. 20B) 
and 76% decrease in distal transcripts (Fig. 20C).  While preliminary results 
support inhibition of HIV transcription by overexpression of p21, future 
experiments are required to confirm that p21 is not acting prior to proviral 
transcription. 
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Figure 20. Overexpression of p21 limits HIV transcription in human CD4+ T 
cells. (A)  Human CD4+ T cells were spinoculated with FUGW or FUGW-flag-p21 
pseudo-typed with VSVG and containing Rev, Gag-Pol, and Tat.  Twenty-four 
hours post transduction whole cell lysates and RNA was collected. Whole cell 
lysates were run on 10% SDS-PAGE.  Membranes were probed with antibodies 
to human p21, then stripped and reprobed with anti-flag and human β-actin. (B-
C)  Human CD4+ T cells were spinoculated with FUGW or FUGW-flag-p21 
psuedo-typed with VSVG and containing Rev, Gag-Pol, and Tat.  Twenty-four 
hours post transduction, cells were spinoculated with NL4.3 HSA psuedotyped 
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with VSVG.  Twenty-four hours post infection RNA was collected. Quantitative 
real time RT-PCR analysis for (B) HIV-1 initiated transcripts and (C) HIV-1 
elongated transcripts, normalized to β-actin expression, was performed.  Relative 
expression was determined using uninfected control expression as a calibrator 
and the 2-ΔΔCT method.  
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2.4  Increased binding of NELF at the HIV LTR in HIV+ elite controllers. 
Infection of CD4+ T cells from HIV+ elite controllers supported less HIV 
transcription compared to CD4+ T cells from seronegative and HIV+ progressors 
(Chen et al., 2011).  Utilizing chromatin isolated from these elite controllers, we 
performed chromatin immunoprecipitation of the promoter proximal region of the 
HIV LTR.  While Pol II binding to the HIV promoter proximal region is equivalent 
in HIV+ elite controllers and seronegative controls, there is a trend of ~25% 
higher binding of NELF at the same region (Fig. 21a-b).  These data suggest p21 
limits HIV transcription at the level of Pol II processivity. 
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Figure 21.  Elevated p21 in HIV+ elite controllers limits HIV transcriptional 
elongation.  Human CD4+T cells from seronegative and HIV+ elite controllers 
were stimulated with IL2 and CD3/CD8 for 5 days.  Following stimulation, 5 x106 
CD4+T were infected with NL4.3 for 7 days as previously described. Cells were 
treated with 1% formaldehyde to cross-link proteins and DNA was sonicated to 
obtain fragments of approximately 200 bp.  Sonicated DNA was 
immunoprecipitated with (A) anti-human RNA Pol II, (B) anti-human NELF B, and 
anti-flag or anti-rabbit IgG as a non-specific control antibody. Qualitative real time 
RT-PCR analysis of the +30-+134 region of the promoter proximal HIV proviral 
DNA was calculated based upon donor specific input DNA standard curves. 
Specific antibody binding was normalized to control antibody binding. 
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2.5   Future directions. 
Our preliminary studies support previous data in which elevated p21 
expression in HIV elite controllers limits HIV transcription.  However, future 
experiments will control for the effects of p21 on HIV proviral integration, by 
establishing HIV infection in human CD4+ T cells prior to p21 overexpression.    
Using this model, we will repeat the experiments above, observing HIV proximal 
and distal transcripts following overexpression.  We expect no defect in 
expression of HIV promoter proximal transcripts, but a decrease in expression of 
HIV distal transcripts.  The architecture of the HIV LTR will be characterized in 
cells overexpressing p21. Chromatin will be isolated and chromatin 
immunoprecipitation will be performed to assess binding of Pol II, P-TEFb, NELF 
and acetylated histones to address binding of positive and negative transcription 
elongation factors and nucleosome modifications. We expect that p21 
overexpression in vitro will result in a paused polymerase complex at the HIV 
LTR, and decreased Pol II binding downstream, indicating a block in processivity.   
p21 inhibits cell cycle kinases and controls G1 arrest (Davies et al., 2013; 
Mbopi-Keou et al., 2002).  As such, in future experiments it will be important to 
control for cell viability.  While no obvious effect on cell viability was observed in 
the above experiments, it will be important to monitor viability via trypan blue 
exclusion and viable cell counts in future experiments.    
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DISCUSSION 
Summary of results 
We have previously shown that the receptor tyrosine kinase RON inhibits 
HIV transcription using human monocyte cell lines overexpressing RON (Klatt et 
al., 2008), and that HIV-associated encephalitis correlates with reduced RON 
expression in brain tissue post autopsy (Lee et al., 2004).  However, post autopsy 
tissue provides only a glimpse into the final stages of chronic HIV infection and 
inflammation, and provides little illumination into the steps leading to the 
development of inflammation and loss of RON expression.   
We expanded upon our previous findings using a temporal model of SIV-
associated CNS disease in pigtail macaques (Clements et al., 2011; Clements et 
al., 2008), and an in vitro tissue-resident macrophage cell model.  Using the SIV 
model we observed dysregulation of RON throughout the course of infection, 
rather than just at the terminal stages of disease.  Loss of RON expression 
correlated with greater viral load, inflammatory cytokine expression, and 
presence of inflammatory lesions in the brain.  Tissue-resident macrophages, 
isolated from human tonsil tissue, allowed us to manipulate conditions and build 
upon our correlative in vivo data.  Tonsil derived macrophages treated with MSP, 
the ligand for RON, suppressed inflammatory cytokine expression and expressed 
high levels of arginase.  HIV transcription was inhibited by both ligand-dependent 
and independent RON signaling in vitro, and RON expression was decreased 
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following HIV infection in vitro.  Together these data suggest that RON limits HIV 
transcription and protects against HIV-associated inflammation, but persistent 
HIV replication results in a decrease of RON expression, compromising its role in 
inflammation homeostasis.   
RON regulates tissue inflammation 
A loss of RON expression correlates with inflammation in both pathogen-
induced and autoimmune-associated inflammatory diseases (Caldwell et al., 
2008; Correll et al., 1997; Lutz et al., 2002; McDowell et al., 2002; Nikolaidis et 
al., 2011; Tsutsui et al., 2005), suggesting a more global role for RON in other 
HIV-associated end organ diseases.  For example, RON expression is reduced in 
brain tissues of patients with HIV-associated encephalitis and in individuals with 
autoimmune inflammation due to multiple sclerosis (Lee et al., 2004; Tsutsui et 
al., 2005). 
RON is also expressed on alveolar macrophages, and RON knock-out 
mice challenged intra-nasally with LPS had an elevated acute lung injury 
response with greater TNFα and NO production and tissue damage (McDowell et 
al., 2002; Nikolaidis et al., 2011).  Based on the protective role RON plays in the 
lung, targeting of RON by HIV may contribute to higher incidence of opportunistic 
lung infections, including tuberculosis (TB).  TB accounts for 13% of AIDS related 
deaths (UNAIDS, 2012).  HIV-infected individuals are more likely than HIV 
serognegative TB patients to progress from latent to active tuberculosis (Beck et 
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al., 2001; Gingo and Morris, 2013; Huang and Crothers, 2009).  In addition to 
opportunistic lung inflammation, HIV-infected individuals are more susceptible to 
chronic obstructive pulmonary disease, acute bronchitis, and emphysema (Gingo 
and Morris, 2013; Hull et al., 2008); all diseases with a strong inflammatory 
component and that might be mitigated by RON activity. 
RON was first described in the male genital tract (Ronsin et al., 1993); and 
RON expression has been observed in rat sperm, and murine male and female 
genital tracts (Hess et al., 2003; Ohshiro et al., 1996).  Co-infections at the 
genital mucosa are prevalent in HIV-infected individuals (Mayer and Venkatesh, 
2011).  Pre-existing infection with ulcerative mucosal pathogens, such as syphilis 
and Herpes simplex type 2, results in a breakdown of protective mucosa.  
Infection with inflammatory mucosal pathogens, such as Neisseria gonorrhoeae 
and Chlamydia trachomatis, results in elevated recruitment of immune cells 
which provide a surplus of CD4+ targets for HIV.  HIV targeting of RON 
expression may contribute to compromised immunity and the resulting 
susceptibility to opportunistic infections at the genital mucosa.   
RON signaling  
Evidence of MSP-independent RON signaling has been demonstrated in 
overexpression systems (Klatt et al., 2008; Wei et al., 2005b) as well as naturally 
occurring extracellular domain mutants of RON (Yao et al., 2013).  RON is 
overexpressed in a number of human tumors (Lu et al., 2007), and mutations in 
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the extracellular domain, or presence of only the intracellular signaling domain, 
short form RON (Bardella et al., 2004), confer constitutive signaling of RON.  In 
this context, RON signaling induces greater cell spreading and proliferation, 
which contributes in growth and persistence of human tumors.  It is interesting to 
note that RON does not induce oncogenic transformation of cells, but instead 
results in increased tumorigenic activity within the existing tumor (Yao et al., 
2013).  Utilizing endogenous RON expression in tonsil derived tissue-resident 
macrophages; we were able to examine both ligand-dependent and independent 
RON expression, through the use of RON siRNA knockdown.    RON knockdown 
in tissue-resident macrophages results in greater HIV expression compared to 
cells treated with nonspecific control siRNA, indicating that RON itself provides a 
protective block in HIV replication.   While RON isoforms expressed in human 
tumors exhibit constitutive signaling, it is unclear if RON MSP-independent 
signaling in tissue-resident macrophages is regulated.  It is possible that other, 
non-MSP serum proteins also activate RON. 
Clinical implication of RON research 
RON is an attractive therapeutic target (Lu et al., 2007; Ma et al., 2010; 
Yao et al., 2013) for addressing HIV-associated inflammation and HIV disease 
progression.  HIV Tat targets RON for proteasome mediated degradation 
(Kalantari et al., 2008), and targeting HIV Tat may prevent loss of RON 
expression.  RON is protective when retained during chronic infection, as 
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suggested by the correlation in RON expression and lack of CNS lesions.  HIV 
also targets RON at the mRNA level, and future studies should elucidate the 
precise mechanism of how HIV modulates RON expression.  MSP, RON ligand, 
is regulated by cleavage from pro-MSP to functional MSP by proteases 
(Kawaguchi et al., 2009), which could be manipulated to increase the available 
cleaved bio-active MSP.   The primary caveats in targeting RON expression 
would be a possible non-specific immune suppression and the correlation in 
elevated RON expression in certain tumors.   It would therefore be preferable to 
target RON expression on tissue-resident macrophages or within a specific 
tissue to avoid a more general effect of RON expression on epithelial cells.   
While induction of RON expression is an attractive candidate for a therapeutic 
approach, preliminary data to determine factors that induce RON expression in 
vitro has been inconclusive; and further research will be required to understand 
regulation of the RON expression.  
During chronic HIV infection, latently infected macrophages may 
contribute to the rebound in HIV observed after treatment interruption (Finzi et 
al., 1997; Wong et al., 1997).  Maintenance of transcriptional latency in these 
cells may provide a means to prevent viral rebound.  Targeting RON 
therapeutically has the potential to control transcription of HIV as well as genes 
associated with inflammation. 
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Model 
We propose the following model to describe the HIV-associated 
inflammation within the CNS, which we suggest is a paradigm for inflammation in 
other tissue microenvironments.   
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Figure 22.   HIV induces inflammation in the tissue microenvironment.  HIV 
crosses the blood brain barrier, either as free virion or through infected circulating 
immune cells.  An acute inflammatory response occurs resulting in the production 
of inflammatory cytokines (including:  IL-12, IL-1β, and TNFα) and NO by 
macrophages.  These factors aid in the immune response, but result in further 
induction of HIV transcription within infected cells and damage to surrounding 
neural tissue and astrocytes.  Soluble factors released by dying astrocytes and 
neurons, including inflammatory cytokines, further activate macrophages to 
continue producing inflammatory cytokines.   
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Figure 23.   Resolution of inflammation in the tissue microenvironment.  
Resolution of the inflammatory response is mediated by intrinsic factors such as 
RON, which limit inflammation.  RON signaling suppresses the production of 
inflammatory cytokines while inducing expression of factors that mediate tissue 
repair (such as Arginase and SRA).  Additionally, RON signaling inhibits HIV 
replication.   
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Figure 24.  Loss of RON expression results in HIV-associated inflammation.  
Chronic HIV infection results decreased RON expression, leading to continued 
expression of inflammatory factors by tissue resident macrophages, recruitment 
of classical inflammatory macrophages, astrocytes, and neurons.  Without the 
balance provided by the expression of anti-inflammatory and repair mediators, 
these factors further activate macrophage inflammatory cytokine expression, 
cause additional damage to surrounding astrocytes and neurons, and activate 
HIV transcription.  Taken together, these factors would perpetuate the immune 
dysfunction and inflammation associated with chronic HIV infection.   
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Understanding mechanisms that control HIV in elite controllers 
 Understanding naturally occurring control of HIV may elucidate 
mechanisms that can be exploited to increase quality of life of HIV+ individuals.  
While no single clear mechanism has been identified as the sole determinant of 
whether an HIV-infected individual will become a controller, there are a number of 
immunological correlates in cohorts of elite controllers (Autran et al., 2011; 
Brombin et al., 2013; O'Connell et al., 2009).  There is a preponderance of the 
MHC haplotype HLA B*5701 among elite controllers (O'Connell et al., 2010).  
Moreover, CD8 T cells from elite controllers tend to respond to gag instead of env 
(Buckheit et al., 2013; Buzon et al., 2013; Ferre et al., 2010; Turk et al., 2013).  A 
more recent observation indicated that the cyclin dependent kinase p21 is 
overexpressed in a subset of HIV+ elite controllers (Chen et al., 2011).  
Overexpression of p21 in elite controllers correlates with suppressed expression 
of HIV elongated transcripts.  Furthermore, enhanced NELF binding to the HIV 
LTR in elite controller T cells, suggest that elevated p21 expression is inducing a 
Pol II pause, which in turn limits productive elongation.  It may be possible to 
induce expression of p21 in HIV+ individuals to recapitulate this phenotype.  p21 
expression is regulated by p53 in vitro (Elbendary et al., 1996; Macleod et al., 
1995; Sabbatini et al., 1995), and maybe used therapeutically to overexpress 
p21.   Wild-type p53 adeno-viral based gene therapy is currently used in China 
as a cancer therapy, and p53 drugs target and restore the function of mutant p53 
in tumors (Essmann and Schulze-Osthoff, 2012).  Our preliminary studies have 
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indicated that p21 can be overexpressed in human CD4+ T cells, and induced 
overexpression results in suppression of HIV transcription.   
While p21 is a general cellular factor involved in regulation of cyclin 
dependent kinases and, therefore, cell cycle, it is not unheard of to exploit 
general cellular mechanisms to treat disease.  HDACi have been used as an 
anti-epileptic agent and more recently in cancer therapy (Gottlicher, 2004), with 
minimal side effects.  HDACi have also been tested in clinical trials to purge 
latent HIV, though the results in these trials have not indicated HDACi as a clear 
cut strategy to eliminate HIV reservoirs (Rasmussen et al., 2013).  Targeting of 
specific cellular mechanism may be possible due to redundancies in these 
mechanisms, which permit general cellular processes to occur in spite of 
inhibition.  The presence of elevated p21 in elite controllers further suggests the 
manipulation of this mechanism will not result in an obvious defect in cell cycle 
processes. 
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APPENDIX A 
Macrophage polarization and Ron expression 
 
 Tissue-resident macrophages expressing RON have wound healing, 
repair, and protective functions similar to alternatively activated macrophages.  
RON signaling induces the production of arginase and inhibition of LPS induced 
iNOS (Chen et al., 1998; Morrison and Correll, 2002).  The arginase-iNOS axis is 
also used to distinguish AM and CM subsets of macrophages in murine 
macrophage systems (Ishii et al., 2009; Martinez et al., 2006).  In vitro 
polarization of murine bone marrow derived macrophages induces an AM 
phenotype, characterized by the expression of arginase-1 and inhibition of iNOS.  
RON expression on macrophages is limited to tissue-resident macrophages, and 
is not expressed on MDM from peripheral blood. We posited that culturing murine 
bone marrow derived macrophages and human MDM in polarizing conditions will 
induce RON expression in vitro.   
 To test our hypothesis, bone marrow derived macrophages and human 
MDM were treated with the AM polarizing cytokine IL-4 or the CM polarizing 
cytokines IFNγ/TNFα to determine if polarizing conditions induced RON 
expression in vitro.  To obtain bone marrow derived macrophages, bone marrow 
cells were flushed from mouse femurs and cultured in complete medium RPMI 
supplemented with 20% L929 conditioned media as a source of murine M-CSF 
(Shaik-Dasthagirisaheb et al., 2013).  MDM were prepared from PBMC by 
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enriching for adherent cells following overnight culture in complete medium 
RPMI.   
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Figure 25.  Polarization of murine bone marrow derived macrophages 
induces iNOS and Arg-1 expression but does not induce RON expression.   
Murine bone marrow derived macrophages were cultured in complete medium 
RPMI supplemented with 20% L929 conditioned media as a source of murine M-
CSF.  After 7 days in culture, bone marrow derived macrophages were dislodged 
and replated in antibiotic free RPMI, and treated with mIFNγ (20ng/ml, R&D 
Systems) or mIL-4 (20ng/ml, R&D Systems) for 18 hours and RNA was collected. 
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Data represents a single cell preparation with triplicate RT-PCR reactions. (A) 
Quantitative real time RT-PCR analysis for Nos2 expression, normalized to β-
actin expression, was performed using cDNA from bone marrow derived 
macrophages.  Relative expression was determined using uninfected control 
expression as a calibrator and the 2-ΔΔct method.  Polarization with IFNγ/TNFα 
induced iNOS expression.  (B) Quantitative real time RT-PCR analysis for Arg-1 
expression, normalized to β-actin expression, was performed using cDNA from 
bone marrow derived macrophages.  Relative expression was determined using 
uninfected control expression as a calibrator and the 2-ΔΔct method.  Polarization 
with IL-4 induced Arg-1 expression.  (C)  Qualitative real time RT-PCR analysis of 
RON transcripts was normalized to β-actin, and expression was calculated based 
upon RON and β-actin plasmid DNA standard curves.  RON expression in 
untreated murine bone marrow derived macrophages is less than 1,000 x lower 
than expression detected in tonsil derived tissue-resident macrophages.  
Polarization with IFNγ and TNFα or IL-4 did not significantly altered RON 
expression in bone marrow derived macrophages.   
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Figure 26.  IFNγ/TNFα polarization of human monocyte derived 
macrophages induces iNOS production but does not induce RON 
expression.   Primary human MDM were matured on plastic for 7 days.  Cells 
were treated with hIFNγ (20ng/ml, R&D Systems) or hIL-4 (20ng/ml, R&D 
Systems) for 18 hours and RNA was collected. Data represents a single donor 
with triplicate PCR reactions. (A) Quantitative real time RT-PCR analysis for 
Nos2 expression, normalized to β-actin expression, was performed using cDNA 
from MDM.  Relative expression was determined using uninfected control 
expression as a calibrator and the 2-ΔΔct method.  Polarization with IFNγ/TNFα 
induced iNOS expression.  Arginase was not detected (data not shown).   
 (B)  Qualitative real time RT-PCR analysis of RON transcripts was normalized to 
β-actin, and expression was calculated based upon RON and β-actin plasmid 
DNA standard curves.  RON expression in untreated MDM is less than 1,000 x 
lower than expression detected in tonsil derived tissue-resident macrophages.  
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Polarization with IFNγ and TNFα or IL-4 did not significantly altered RON 
expression in MDM.   
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Summary of results 
RON expression has been reported to be limited to tissue-resident 
macrophages (Correll et al., 2004), and RON signaling is upstream of several 
genes that are associated with AM function (Morrison and Correll, 2002).  
Treatment with IL-4, which induces AM phenotypes in murine bone marrow 
derived macrophages, does not induce RON expression.  Therefore, our initial 
hypothesis, that polarizing macrophages with cytokine treatments will alter RON 
expression appears to be wrong.  
The complex combination of growth factors, cytokines, matrix proteins, 
and organ specific cell types and stroma within the tissue microenvironment, as 
well as the possible contribution of yolk sac derived progenitors (Ginhoux et al., 
2010; Hashimoto et al., 2013; Schulz et al., 2012), may be difficult to reproduce 
in vitro and this could limit our ability to induce RON expression. Furthermore, 
macrophages are heterogeneous and those selected by the conditions outlined 
in this set of experiments may not support the full spectrum of alternative 
macrophage phenotypes including RON expressing tissue-resident 
macrophages.  
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